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Abstract:  
Loss of endothelial thrombomodulin (TM) function is associated with macrovascular, 
microvascular, and inflammatory diseases. Loss of TM function impairs the generation of the 
anticoagulant protease activated protein C (aPC), which conveys important neuroprotective 
effects. Yet, the physiological relevance and the mechanism through which the TM-aPC 
system maintains nerve function remain unknown. Using mice expressing a mutant TM 
(TMPro/Pro) resulting in markedly reduced aPC generation we uncover a previously unknown 
function of TM-mediated aPC-generation for physiological nociception. While conductivity of 
isolated peripheral nerves is normal in TMPro/Pro mice, loss of TM-dependent aPC generation 
impairs myelination, increases ROS generation, and disrupts mitochondrial function within 
the CNS in unchallenged (non-diseased) mice. Substitution of aPC in TMPro/Pro mice 
normalises nociception as well as myelination, reduces ROS-generation, and ameliorates 
mitochondrial function within the CNS.  
To evaluate whether functional impairment of the TM-PC system is of pathophysiological 
relevance we evaluated the impact of impaired aPC-generation on peripheral neuropathy 
and on demyelinating disease models within the CNS. In experimental diabetic neuropathy, a 
disease of the peripheral nerve system, impaired TM-dependent aPC-generation does not 
aggravate the disease progression, consistent with a primary myelination defect within the 
CNS. Contrary, in a murine model of experimental autoimmune encephalitis (EAE) impaired 
TM-dependent PC-generation aggravates the disease progression. Impaired endogenous 
aPC generation enhances ROS generation and reduces markers reflecting mitochondrial 
mass (porin) and biogenesis (PGC1α). This establishes that endogenous aPC generation 
protects from neuronal demyelination and mitochondrial dysfunction in EAE. Restoring 
endogenous aPC levels or genetically restraining mitochondrial ROS generation partially 
reverses the disease severity in TMPro/Pro mice. Intriguingly, therapeutic application of soluble 
TM (solulin) conveys pronounced neuroprotection, delaying the disease onset and 
diminishing the disease severity in TMPro/Pro mice. The effect of soluble TM is superior to that 
of aPC or ROS-inhibition. A similar effect of soluble TM is apparent in TM wild-type mice, 
corroborating the therapeutic potential of soluble TM. Of note, soluble TM improves 
myelination even in a non-immunological mediated demyelination model (cuprizone-induced 
demyelination), establishing that soluble TM protects myelin independent of its known 
immune-modulatory function. Our results identify TM-dependent aPC activation as a new 
physiological pathway regulating neuronal function and as an important pharmacological 
target to alleviate impaired nociception and demyelinating diseases of the CNS. 
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Zusammenfassung 
Der Funktionsverlust von endothelialen Thrombomodulin (TM) ist kennzeichnend für makro- 
und mikrovaskulären Erkrankungen. Der Funktionsverlust von TM beeinträchtigt die 
Aktivierung des gerinnungshemmenden aPC (aktiviertes Protein C). aPC vermittelt zell-
protektive Effekte in verschiedenen Zellsystemen und Erkrankungsmodellen. Insbesondere 
die nephro- und neuroprotektiven Eigenschaften des aPC sind durch zahlreiche Arbeiten 
belegt. Dis physiologische Bedeutung des TM-PC Systems für die neuronal Funktion sowie 
der genaue Wirkungsmechanismus des TM-PC Systems auf die Funktion der Nerven ist 
jedoch nach wie vor unbekannt.  
 
Unter Verwendung von Mäusen, die eine Punktmutation im TM (TMPro/Pro) aufweisen, was zu 
deutlich reduzierter aPC-Aktivierung führt (< 1% im Vergleich zu wt Tieren), haben wir eine 
bisher unbekannte Funktion der TM-vermittelten aPC Generation für die physiologische 
Schmerzwahrnehmung aufgedeckt. Während die Leitfähigkeit von isolierten peripheren 
Nerven in TMPro/Pro-Mäusen normal ist, zeigen sich durch den Verlust der TM-abhängigen 
aPC Generation Beeinträchtigtigungen in der Myelinisierung, erhöhte ROS (reactive oxygen 
species) Produktion und gestörte Funktionen der Mitochondrien innerhalb des ZNS in bereits 
nicht erkrankten Mäusen. Durch Substitution von aPC in TMPro/Pro Mäusen (i.p. Applikation) 
normalisiert sich die Schmerzwahrnehmung sowie auch die Myelinisierung, es wird 
vermindert ROS generiert und die mitochondrialen Dysfunktionen innerhalb des ZNS werden 
geringer. Anhand dieser Studien identifizieren wir einen neues und physiologisch relevantes 
System, das TM-PC-System, das die Schmerzwahrnehmung reguliert. 
 
Um zu beurteilen, in wie weit die Funktionsstörungen innerhalb des ZNS bei Mäusen mit 
eingeschränkter aPC Generation von pathophysiologischer Relevanz sind, untersuchen wir 
im weiteren Verlauf die Auswirkungen von eingeschränkter PC-Aktivierung auf die periphere 
Neuropathie und auf demyelinisierende Erkrankungsmodelle, wie EAE, innerhalb des ZNS. 
In Tiermodellen zur experimentellen diabetischen Nephropathie trägt die beeinträchtigte TM-
abhängige aPC Generation nicht zum beschleunigten Fortschreiten der Erkrankung bei, was 
im Einklang mit einem primären Myelinisierungsdefekt innerhalb des ZNS ist. Im Gegensatz 
dazu steht das Mausmodell der Multiplen Sklerose, die experimentelle autoimmunene 
Enzephalitis (EAE). In diesem Erkrankungsmodell beschleunigt die beeinträchtigte TM-
abhängige PC-Generation das Fortschreiten der Krankheit. Beeinträchtigte endogene aPC-
6 
 
Erzeugung führt zu erhöhter ROS-Produktion und zur Störungen der mitochondrialen 
Funktion, was durch die Verringerung der mitochondrialen Masse (Porin) und der 
mitochondrialen Biogenese (PGC1α) wiedergespiegelt wird. Diese Ergebnisse zeigen, dass 
die endogene aPC-Generation vor neuronalen Demyelinisierungserkrankungen und vor 
mitochondrialen Dysfunktionen im EAE-Modell schützt. Durch Ersetzen von endogenem aPC 
(aPC Injektion) oder durch genetisches Ausschalten der mitochondrialen ROS-Erzeugung 
(p66Shc Mangel) ist die Schwere der EAE-Erkrankung in TMPro/Pro Mäusen teilweise 
umkehrbar. 
Interessanterweise vermittelt die therapeutische Anwendung von löslichem TM (Solulin) 
ausgeprägte Neuroprotektion, gekennzeichnet durch eine Verzögerung des 
Erkrankungsausbruchs und eine Verringerung der klinischen Erkrankungssymptome in 
TMPro/Pro-Mäusen. Ein ähnlicher Effekt von löslichem TM zeigt sich in TM-Wildtyp-Mäusen, 
was das therapeutische Potential von löslichem Thrombomodulin belegt.  
Des Weiteren ist zu beobachten, dass lösliches Thrombomodulin die Myelinisierung 
ebenfalls in einem nicht-immunologischen Demyelinisierungsmodell (Cuprizon induzierte 
Demyelinisierung) verbessert. Cuprizon (bis-Cyclohexanon-Oxaldihydrozon) ist ein Kupfer-
Chelator, der bei 5-wöchiger Beigabe im Futter zu Demyelinisierungserscheinungen im 
Corpus callosum des Gehirns führt. Diese neuen Erkenntnisse zeigen erstmals, dass 
lösliches TM Myelin unabhängig von seiner immun-modulatorischen Funktion vor 
demylenisierenden Erkrankungen schützt.  
 
Zusammenfassend identifizieren unsere Ergebnisse die TM-abhängige PC-Aktivierung als 
ein neues physiologisch relevantes System, dass die neuronale Funktion reguliert, und als 
eine wichtige pharmakologische Zielstruktur. Die weitere Untersuchung dieses Ansatzes 
könnte neue Therapieansätze für demyelinisierenden Erkrankungen aufzeigen. 
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List of abbreviations 
aPC activated protein C 
BBB blood brain barrier 
BSA bovine serum albumin 
C control 
cDNA complementary deoxyribonucleic acid 
CL Cardiolipin 
CNS Central Nervous System 
d days 
DAB 3,3’-diaminobenzidine 
DAPI 4′,6-Diamidin-2-phenylindol 
ddH2O double destilled water 
dH2O destilled water 
DEPC diethylpyrocarbonat 
DMEM dulbecco´s modified eagle´s medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTPs desoxynucleosid triphosphates 
DSPN diabetic sensorimotoric polyneuropathy 
DTT dithiothreitol 
EAE experimental autoimmune encephalomyelitis 
EDTA ethylenediamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
EPCR endothelial cell protein C receptor 
FBS fetal bovine serum 
FCS fetal calf serum 
g gravitational acceleration 
Glu glutamate 
HBSS hanks' balanced salt solution 
HRP horseradish peroxidase 
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H2O2 hydrogen peroxide 
IgG immunoglobulin G 
i.p. intraperitoneal 
kb kilobase(s) 
MgCl2 magnesium chloride 
MOG myelin oligodendrocyte glycoprotein 
mRNA messenger ribonucleic acid 
MS multiple sclerosis 
PAR protease-activated receptor  
PBS phosphate buffered saline 
PC protein C 
PCR polymerase chain reaction 
PGC1α         Peroxisome proliferative activated receptor gamma coactivator 1α 
 
Pro proline 
PVDC Polyvinylidenchloride 
rpm revolutions per minute 
RT room temperature 
RT-PCR reverse transcription polymerase chain reaction 
SDS sodium dodecyl sulfate 
s.e.m. standard error of the mean 
SOD1 superoxide dismutase 1 
sTM soluble thrombomodulin 
TBE  tris borate EDTA 
TE  tris-HCL EDTA 
TF tissue factor 
TM  thrombomodulin 
U  units 
VDAC1 Voltage Dependent Anion Channel 1 
Wt wildtype 
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1 Introduction 
 
1.1 Coagulation  
The blood coagulation system comprises three basic elements: 1. platelet adhesion, 
activation and aggregation, 2. fibrin formation, and 3. fibrinolysis. These elements interact 
with each other and under physiological conditions vascular integrity is maintained and blood 
flow to tissues is unimpaired by clotting [1]. Under pathophysiological conditions, blood 
coagulation becomes activated through the interaction of three components: an altered 
vessel wall, an impaired and/or changed pattern of blood flow and/or an altered blood 
composition (known as the “Virchow’s trias”). 
 
Injury to the blood vessel wall causes disruption of its endothelial layer, resulting in the 
exposure of the underlying extracellular matrix. Within the matrix, both von Willebrand factor 
(vWF) and collagen are present and following exposure they will bind to specific receptors, 
glycoproteins (GP), present on the surface of the platelets. Dependent on the flow within the 
vessel other glycoproteins are involved in the adhesion of the platelets to the vessel wall. 
Formation of the tissue factor-factor VII(a) complex drives the intrinsic pathway of 
coagulation to form thrombin and fibrin. Platelet adhesion, activation, and interactions with 
leukocytes accelerate the process of thrombin formation yielding activated coagulation 
proteases such as factor XIa that amplify thrombin generation (Fig 1).  
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Fig. 1. Schematic overview of the blood coagulation cascade (adapted from Spronk et al., 2003). The 
model is divided in the intrinsic, extrinsic, and common pathway. Active forms of blood coagulation factors 
are denoted by a small ‘a’ added to the roman number. TF, tissue factor; PL, phospholipid; HMWK, high 
molecular weight kininogen. Positive feedback loops by thrombin (dotted lines), FIXa (dashed-dotted line), 
and FXa (dashed line) are indicated in grey. Y indicates inhibition by activated protein C (APC) and tissue 
factor pathway inhibitor (TFPI). 
1.2 Thrombomodulin structure 
Thrombomodulin (TM), a type 1 transmembrane molecule expressed predominately on 
endothelial cells, conveys an important function in regulating the coagulation system, 
inflammation, fibrinolysis and cellular proliferation. TM binds and inhibits the procoagulant 
function of the key coagulation protease thrombin. When bound to TM thrombin obtains 
substrate specificity for protein C (PC), generating activated PC (aPC). 
Encoded by an intronless gene, the mature single-chain glycoprotein in humans is 557 amino 
acids long, structurally organized into 5 distinct domains (Fig. 2). TM has a short cytoplasmic 
tail followed by a well-conserved membrane-spanning region and a serine/threonine-rich 
domain with sites for O-linked glycosylation, which support the attachment of a chondroitin 
sulfate (CS). Adjacent to serine/threonine-rich region is the best-characterized domain, which 
comprises six epidermal growth factor (EGF)-like repeats.  
EGF like repeats 3, 4, 5, and 6 (EGF3 to 6) have been studied in detail by several groups. 
Via its anion-binding site, exosite 1, thrombin binds to EGF5 through EGF6. EGF-like repeats 
4-6 are essential in activation of protein C (Fig. 2) by thrombin, while EGF-like repeats 3-6 
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are required for activation of TAFI (thrombin activatable fibrinolysis inhibitor, also known as 
carboxypeptidase B2) [2, 3]. At the N-terminus of the molecule and joined to the first EGF-
like repeat by a 72- amino acid residue hydrophobic stretch, there is a 154-amino acid 
residue module with homology to other C-type lectins [4, 5].  
 
Fig. 2: Structure of thrombomodulin (from Weiler et al., 2003) 
See text for more details 
1.3 Thrombomodulin and PC-system 
The activation of PC by the TM-thrombin complex is about 10-fold accelerated in the 
presence of the co-receptor EPCR (endothelial protein C receptor). The serine protease aPC 
initiates a negative feedback mechanism of coagulation activation by inactivating factor Va 
and VIIIa. Independent of its well-known anticoagulant activity APC acts directly on cells and 
alters gene expression, inhibits apoptosis, and down-regulates inflammation via protease 
activated receptor-1 (PAR-1) and EPCR (Fig. 3). PAR-1 is a member of the 7 
transmembrane domain G-protein coupled receptor family, and its activation requires 
cleavage at a specific site within its extracellular amino terminus. This cleavage produces a 
new aminoterminus, which then acts as its own tethered ligand. PAR-1 was first discovered 
as a human platelet thrombin receptor [6] and today four homologous PARs (PAR-1, 2, 3, 
and 4) are known in man and rodents [7-9]. The tissue and cell specific expression as well as 
different activating proteases allow differential effects, which remain incompletely understood 
[10]. Direct neuronal protective effects through aPC require signaling via PAR-1 and PAR-3 
[11]. 
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Fig. 3: Schematic models of PC activation and aPC activities (adapted from Mosnier et al., 2007)  
Protein C and various cellular receptors are localized to the cell surface where they initiate biochemical 
signals for transformation. Among these reactions protein C gets activated and conveys it´s either 
anticoagulant or cytoprotective activity (Fig. 1 A-C). To activate PC, thrombin (IIa) binds to thrombomodulin. 
Binding of protein C to its endothelial receptor (EPCR), enhances activation of protein C. (A). Dissociation of 
aPC from EPCR allows anticoagulant activity of aPC only when bound to protein or lipid cofactors. In the 
presence of cofactors (protein S, fV) aPC cleaves fVa and fVIIIa, thus dampening coagulation activation (B). 
Retention of aPC bound to EPCR allows various cellular activities. To achieve cytoprotective effects of aPC 
the cellular receptors EPCR and PAR-1 are required on endothelial cells, but other receptors (e.g. PAR-3, 
S1P1) are required for its pleiotropic effects on other cell types. APC´s cytoprotective activities include anti-
inflammatory and antiapoptotic activities, alterations in gene expression, and protection of endothelial barrier 
function (C).  
1.4 TM-PC system and neuroprotection 
1.4.1 TM-PC system and stroke 
APC can only act on cells inside the central nervous system by passing the blood brain 
barrier (BBB). The transport of aPC across the BBB is mediated by EPCR [12].  
Cytoprotective efficacy of aPC has been shown in a variety of disease models. In the context 
of stroke aPC’s neuroprotective effect requires signalling via PAR3 and is associated with 
reduced mitochondrial apoptosis [13]. The cytoprotective properties of aPC in stroke are 
independent of its anticoagulant activities. An aPC mutant largely devoid of its anticoagulant 
function but still signaling competent improved neurological scores, reduced bleeding, 
cerebral infarct area and oedema ratio [14]. Further, the efficacy and safety of an aPC-
variant with reduced anticoagulant function (3K3A-aPC) is evaluated in clinical stroke studies 
(NCT01660230; NCT02222714). However, the intracellular signalling pathways and 
consequences of aPC signalling within the CNS are sparse at best. Furthermore, it is not 
known whether TM and / or aPC have a physiological role for neuronal function in the CNS, 
e.g. in the absence of disease promoting stimuli  
16 
 
1.4.2 TM-PC system in diabetic neuropathy/peripheral neuropathy 
Macrovascular and microvascular complications are associated with loss of endothelial 
thrombomodulin (TM) function [15, 16]. In the context of diabetic nephropathy plasma levels 
of soluble TM, thought to reflect loss of endothelial TM, and plasma levels of activated 
protein C (aPC) correlate positively or inversely, respectively, with albuminuria [17, 18]. 
Studies in mice demonstrated that loss of TM-dependent protein C (PC) activation 
accelerates diabetic nephropathy [19-21]. Mechanistically, aPC reduces glucose induced 
ROS-generation in endothelial cells and podocytes, thus dampening glucose mediated 
glomerular injury. While these effects depend on signalling via PAR1 and EPCR in 
endothelial cells, signalling via PAR3 and PAR2 (human) or PAR1 (mouse) is required in 
podocytes (highly specialised epithelial cells within the glomeruli), reflecting the cell-
specificity of PAR-dependent signalling [22-24]. While these studies provided mechanistic 
insight into the role of the TM-PC system for glomerular microvascular injury, the relevance 
of the TM-PC system for other microvascular complications in the context of diabetes 
remains unknown.  
Reduced expression of TM in perineuronal microvessels of patients with diabetic neuropathy 
has been reported [25], suggesting that TM-dependent PC activation may modulate neuronal 
function akin to its role in glomeruli. Diabetic neuropathy is a chronic illness of the peripheral 
nerves and one of the most frequent and compromising complications of diabetes mellitus 
(DM) [26]. [27, 28]. International epidemiological data suggest that the incidence of neural 
dysfunction is about 30% in diabetic patients.  The most common manifestation of a 
neuropathy in DM is the diabetic sensorimotoric polyneuropathy (DSPN) with impaired 
nociception. DSPN is a mixed neuropathy with involvement of different fibers: sensitive, 
vegetative and motor neurons. It manifests itself in a symmetrical fashion affecting 
particularly the distal extremities (predominately the legs). DSPN results in impaired 
perception of touch, pain and temperature sensation [29, 30]. Deficits with reduction or loss 
of these qualities of perception are of utmost clinical importance, since they pave the way for 
neuropathic-related foot complications, which is the most frequent cause of amputation in 
industrialized countries. 
Unfortunately, effective therapeutic options for diabetic neuropathy as well as other 
peripheral neuropathies are lacking. Hence, new mechanistic insights are required which 
may pave the ground for future therapeutic developments. Of note, PARs are widely 
expressed and their functional relevance within the peripheral and central nervous system is 
established [31-33]. Thus, peripheral PAR2 stimulation results in thermal and mechanical 
hyperalgesia and increased nociceptor activation, while PAR1 stimulation does not cause 
hyperalgesia, but increases the nociceptive threshold to mechanical or thermal stimulation 
[34, 35]. While the relevance of PARs for nociception is established, the impact of 
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coagulation proteases in general, and the TM-PC system in particular, on nociception 
remains unknown.  
The function of the TM-PC system in nociception may, however, extend beyond its potential 
impact on peripheral nerves. As mentioned above, PARs are expressed within the CNS. 
Furthermore, both thrombin and aPC are known to regulate the function of various cell types 
within the CNS [36-38], including multiple sclerosis (see next section).  
1.4.3 TM-PC system and multiple sclerosis 
Multiple sclerosis (MS) is a severe inflammatory and neuro-degenerating disease of the 
central nervous system, resulting frequently in severe illness and long-lasting disabilities [39]. 
MS affects approximately 0.1 % of the general population [40]. The ratio of women with MS 
to men with the disease is 2 to 1.  
The corresponding animal model “experimental autoimmune encephalomyelitis” (EAE) is 
well-established in neuroscience research and is used to understand the mechanisms 
underlying EAE. The morphological hallmark of MS and EAE are disseminated myelination 
and axonal loss. Several therapeutic approaches have been evaluated with partial success, 
but efficient medical approaches to contain this disabling disease are still lacking [41-43]. 
Hence, new and better therapeutic modalities are urgently needed.  
EAE is an auto-immunological disease but the precise underlying mechanism remains 
unresolved. Several contributing factors have been identified, including activation of the 
coagulation system [44]. Intriguingly, while generally thought to be neuro-protective, the role 
of aPC in EAE remains controversial. Initially, a proteomic study of plaque tissue from human 
MS-patients demonstrated induction of TF and the protein C inhibitor in MS, indicating 
increased coagulation activation paralleled by aPC-inhibition [44]. Subsequent animal studies 
indeed revealed an anti-inflammatory and neuro-protective effect in mice with EAE [45]. 
Likewise, the thrombin mutant W215A/E217A, which enhances TM-dependent PC activation, 
ameliorates EAE severity [40].  
The beneficial effect of the thrombin mutant W215A/E217A, which ameliorated EAE severity, 
suggested that EAE may be therapeutically amendable by targeting the TM-PC system [40]. 
WE (W215A/E217A) thrombin is a recombinant thrombin analogue that contains two amino 
acid mutations, generating an enzyme with significantly reduced procoagulant activity. It´s 
activity toward fibrinogen and the thrombin receptor, protease activated receptor-1 (PAR-1) is 
reduced 19,000−and 1,200−fold, respectively, in vitro [40], [46]. Unlike aPC the thrombin 
mutant W215A/E217A lacks direct anticoagulant function, reducing the risk of undesirable 
haemorrhage. However, generation of aPC by W215A/E217A thrombin depends on 
thrombomodulin (TM), and the impaired function of TM in inflammatory diseases, including 
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MS [47, 48], may impede the efficacy of WE-thrombin. In addition, W215A/E217A thrombin 
has not reached clinical studies and hence its translation into the clinic remains uncertain. 
Soluble TM and variants thereof, such as solulin, are being used in clinical settings or 
evaluated in clinical studies [49, 50]. Solulin (soluble human recombinant thrombomodulin) 
has been optimized by inducing several point mutations (Met388Leu, Arg456Gly, His457Gln, 
Ser474Ala) and a deletion of the last seven amino acids of carboxy terminus, increasing its 
resistance to ROS [51]. Similar to W215A/E217A thrombin soluble TM promotes aPC 
generation on demand, yielding aPC in a temporal and spatial controlled fashion. However, 
unlike W215A/E217A thrombin, soluble TM compensates for an inflammation associated loss 
of endogenous TM-function [47]. Pre-clinical studies demonstrated that solulin reduces 
infarct volume in cerebral artery occlusions models and it decreases infarct volume in 
thrombotic stroke [50].  
 
A recent study unexpectedly questioned a disease-promoting role of impaired endogenous 
aPC-generation. Using an antibody (MPC1609) inhibiting binding of protein C and aPC to 
endothelial phospholipid surfaces the authors demonstrated that inhibiting protein C / aPC 
improves the outcome of EAE [45, 52]. The amelioration of EAE following protein C / aPC 
inhibition was associated with an increase of myeloid derived suppressor cells (MDSCs) and 
suppression of T-cell function [45]. Of note, aPC has been shown to directly interact with 
numerous non-endothelial cells, including neurons, astrocytes, or immune-modulatory cells 
such as monocytes and dendritic cells, via a variety of receptors, involving integrins and 
ApoER2 [53, 54]. The impact of the inhibitory antibody on aPC signalling in these cells is not 
known. In addition, the exact binding site of the antibody used remains unknown and hence 
the fate and consequences of the PC- and aPC-antibody complexes remains uncertain. 
Taken together, this study demonstrated that inhibition of endogenous aPC improves EAE-
outcome in rodents, and hence the impact of endogenous aPC generation in EAE and MS 
remains unknown.  
 
1.4.4 Regulation of ROS by aPC: 
The mechanism of how aPC conveys its protective properties in the EAE model is still 
disputed. Several studies suggest that neurodegenerative MS is linked to mitochondrial 
dysfunction and ROS [55, 56]. Various pathways leading to mitochondrial dysfunction have 
been proposed. Interestingly all involve pathologic opening of the permeability transition pore 
(PTP), which is located in the inner membrane of the mitochondria [57-60]. Specifically, Ca2+ 
overload and mitochondrial ROS exposure (reactive oxygen species) open the PTP resulting 
in disruption mitochondrial structure and function, promoting cell death [61, 62]. The 
mitochondrial p66 isoform of the Shc gene locus (p66Shc) has been proposed to be a 
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potential pore modulator [63] and in the presence of ROS it is targeted to the intermembrane 
space, where it serves as a redox enzyme by oxidising cytochrome c and reducing oxygen 
[64, 65]. It has been shown that p66Shc inhibition confers protection against ROS in various 
disease models including EAE [59, 63, 66]. 
Considering the controversial data regarding aPC in EAE the pathophysiological role of 
endogenous TM-mediated aPC generation in EAE remains unresolved [40, 67]. 
Understanding the pathophysiological relevance of endogenous aPC generation is, however, 
of high translational relevance considering the recent introduction of small-molecule 
anticoagulants, some of which interfere with endogenous aPC generation [68], and the 
evaluation of aPC-variants and soluble TM in clinical studies [49].  
 
1.5 Objectives of this study 
The role of endogenous TM-dependent PC activation for neuronal function remains 
unknown. Hence, we determined the physiological and pathophysiological role of TM-
dependent PC activation. Unexpectedly, we identified a physiological role of TM-dependent 
PC activation for nociception, which is independent of peripheral nerve function but rather 
linked with impaired myelination and mitochondrial dysfunction in the CNS. While this defect, 
which is apparent in healthy mice, does not accelerate diabetic nephropathy, it aggravates 
demyelinating diseases of the CNS. These studies unravel a previously unknown 
physiological function of the TM-PC system for neuronal myelination within the CNS and 
provide new insight into pathomechanisms of demyelinating diseases of the CNS. 
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2 Materials and Methods 
2.1 Chemicals and solutions 
 
Chemical/Solution Company 
Acetic Acid  Sigma-Aldrich, Taufkirchen, Germany 
Agarose, Ultra Pure  Invitrogen, Karlsruhe, Germany 
Ammonium Hydroxide  Sigma-Aldrich, Taufkirchen, Germany 
Antigen Unmasking Solution  Vector Labs, Burlingame, CA, USA 
Boric acid  Sigma-Aldrich, Taufkirchen, Germany 
Bovine Serum Albumin (BSA)  Promega, Mannheim, Germany 
Bovine Serum Albumine, fraction V  Sigma-Aldrich, Taufkirchen, Germany 
Bradford Reagent  Sigma-Aldrich, Taufkirchen, Germany 
Chloroform  Sigma-Aldrich, Taufkirchen, Germany 
Citric Acid  Sigma-Aldrich, Taufkirchen, Germany 
Crsyl Echt Violet  Sigma-Aldrich, Taufkirchen, Germany 
Cytoseal Mounting Medium  Microm, Walldorf, Germany 
2´-Deoxynucleoside 5´-triphosphates 
(dNTPs)  Initrogen, Karlsruhe, Germany 
Diethylpyrocarbonat (DEPC)  Roth, Karlsruhe, Germany 
Dimethyl Sulfoxide (DMSO)  Roth, Karlsruhe, Germany 
EDTA  Sigma-Aldrich, Taufkirchen, Germany 
EGTA  Sigma-Aldrich, Taufkirchen, Germany 
Eosin Y  Roth, Karlsruhe, Germany 
Ethanol  Sigma-Aldrich, Taufkirchen, Germany 
Ethidium Bromide  Sigma-Aldrich, Taufkirchen, Germany 
Formaldehyde (37–40 %)  Roth, Karlsruhe, Germany 
Formalin, 4% Buffered  Roth, Karlsruhe, Germany 
Hematoxylin, Gill’s Formula  Roth, Karlsruhe, Germany 
Hydrogen Peroxide Sigma-Aldrich, Taufkirchen, Germany 
Isopropanol 
Becton Dickinson (BD), Heidelberg, 
Germany 
KH2PO4 Sigma-Aldrich, Taufkirchen, Germany 
KCl (Potassium chloride) Roth, Karlsruhe, Germany 
Ladder, DNA, 100bp – 10kb Promega, Mannheim, Germany 
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Lithium Carbonate  Sigma-Aldrich, Taufkirchen, Germany 
Luxol Fast Blue Sigma-Aldrich, Taufkirchen, Germany 
Magnesium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Magnesium Sulfate Sigma-Aldrich, Taufkirchen, Germany 
MassRuler, DNA Ladder, Low Range Fermentas, St. Leon-Rot, Germany 
2-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany  
Methanol Roth, Karlsruhe, Germany 
Milk Powder Roth, Karlsruhe, Germany 
Na-deoxycholate Sigma-Aldrich, Taufkirchen, Germany 
Na2HPO4(2H2O) Sigma-Aldrich, Taufkirchen, Germany 
Na-fluoride Sigma-Aldrich, Taufkirchen, Germany 
Na-orthovanidate Sigma-Aldrich, Taufkirchen, Germany 
Nitric Acid Roth, Karlsruhe, Germany 
Nonidet-p40 (NP40) Sigma-Aldrich, Taufkirchen, Germany 
Percoll 
GE Healthcare Europe, Freiburg, 
Germany 
Protease Inhibitor Cocktail Roche, Mannheim, Germany 
Protein Ladder (kDa) Fermentas, St. Leon-Rot, Germany 
Proteinase K Sigma-Aldrich, Taufkirchen, Germany 
Re-Blot Plus Strong Solution (10x) Merck-Millipore, Darmstadt, Germany 
RNAlater Ambion, Austin, TX, USA 
Roti Histo-Kitt II Roth, Karlsruhe, Germany 
Silver Nitrate Sigma-Aldrich, Taufkirchen, Germany 
Sodium Acetate Sigma-Aldrich, Taufkirchen, Germany 
Sodium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich, Taufkirchen, Germany 
Sodium Thiosulfate Sigma-Aldrich, Taufkirchen, Germany 
Sucrose Sigma-Aldrich, Taufkirchen, Germany 
TEMED Sigma-Aldrich, Taufkirchen, Germany 
Tetra-Myristoyl Cardiolipin Avanti Polar Lipids, Alabaster, AL, USA 
Tissue Tek, O.C.T. Compound Sakura, Zoeterwonde, The Netherlands 
Tris-HCL Sigma-Aldrich, Taufkirchen, Germany 
TRIZOL Invitrogen, Karlsruhe, Germany 
Vectashield Vector Labs, Burlingame, CA, USA 
Xylol BD, Heidelberg,Germany 
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2.2 Hormones, Proteins, Peptides and Adjuvants 
Protein, peptide, adjuvant Company 
Freund´s Adjuvant, Complete Sigma-Aldrich, Taufkirchen, Germany 
MOG35-55 Bachem, Bubendorf, Germany 
Mycobacterium tuberculosis H37 RA Difco, Detroit, Michigan, USA 
Pertussis toxin from Bordetella Merck-Millipore, Darmstadt, Germany 
Soluble thrombomodulin (Solulin) PAION GmbH, Aachen, Germany 
aPC 
AG Isermann, Magdeburg, Germany 
[69] 
2.3  Antibodies and serum 
Antibody Company Dilution 
rabbit polyclonal anti-mouse 
Nitrotyrosine 
Merck-Millipore, Darmstadt, 
Germany 1:1000 
Mouse monoclonal anti-mouse 
nitrotyrosine 
Santa Cruz Biotechnology, 
Heidelberg, Germany 1:200 
mouse monoclonal anti-mouse 
GAPDH 
Sigma-Aldrich, 
Taufkirchen, Germany 1:1000 
rabbit polyclonal anti-mouse 
MAP2 
Cell Signaling, Danvers, 
MA, USA 1:100 
rabbit polyclonal anti-mouse 
PGC1 alpha 
Abcam, Cambridgeshire, 
UK 1:250 
polyclonal rabbit anti-mouse ß-
actin 
Cell Signaling, Danvers, 
MA, USA 1:1000 
mouse monoclonal anti-mouse 
8-oxo-dG 
Trevigen, Gaithersburg, 
MD, USA 1:250 
rabbit polyclonal anti-mouse 
VDAC1/Porin 
Abcam, Cambridgeshire, 
UK 1:500 
goat anti-rabbit IgG-HRP Abcam, Cambridgeshire, UK 1:2000 
rabbit anti-mouse IgG-HRP Abcam, Cambridgeshire, UK 1:2000 
rabbit anti-goat IgG-HRP Abcam, Cambridgeshire, UK 1:2000 
Fluorescein-goat anti-rabbit 
IgG 
Vector Labs, 
Burlingame, CA, USA 
1:400 
 
 
Fluorescein-horse anti-mouse 
IgG 
Vector Labs, 
Burlingame, CA, USA 1:400 
Texas Red-horse anti-mouse 
IgG 
Vector Labs, 
Burlingame, CA, USA 1:400 
Mito Profile Total OXPHOS 
rodent WB Antibody Cocktail 
Abcam, Cambridgeshire, 
UK 1:250 
Texas Red-goat anti-mouse 
IgG 
Vector Labs, 
Burlingame, CA, USA 1:400 
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2.4 Enzymes 
Enzyme Company 
GoTaq Flexi DNA Polymerase Promega, Mannheim, Germany 
LongAMP Taq DNA Polymerase New England Biolabs, Frankfurt/Main, Germany 
 
2.5  Buffers 
2.5.1 General Buffers 
 
10x PBS: 
 
• 80 g NaCl 
• 2 g KCl 
• 14.4 g Na2HPO4(2H2O) 
• 2.4 g KH2PO4 
 
Make up to 1 litre with dH2O after adjust the pH to 7.4. 
 
10x TBS: 
• 24.2 g Tris base 
• 80 g NaCl 
 
Make up to 1 litre with dH2O after adjust the pH to 7.6 with HCl. 
 
0.5 M EDTA: 
• 186.1 g EDTA 
• 800 ml dH2O 
 
Make up to 1 litre with dH2O after adjusting pH to 8.0 with NaOH. 
5x TBE: 
• 54 g Tris 
• 27.5 g Boric acid 
• 20 ml EDTA (0.5 M) 
 
Make up to 1 litre with dH2O. For TBE working solution (0.5 x) dilute stock 1:10 with dH2O. 
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2.5.2 Luxol Fast Blue stain 
Luxol Fast Blue Solution: 
• 1 g Luxol fast blue 
• 100 ml 95 % ethanol 
• 5 ml 10 % acetic acid 
0.05 % Lithium Carbonate: 
• 0.5 g Li2CO3 
• 1000 ml dH2O 
  
0.25 % Cresyl Echt Violet: 
• 0.25 g Cresyl Echt Violet 
• 100 ml dH2O 
• 10% Acetic acid 
2.5.3 “Karlsson–Schultz” solution [70]:  
2.5 % Glutaraldehyde/4 % Formaldehyde in Phosphate Buffer pH 7.3  
 
Paraformaldehyde (16 %) stock solution:  
• Mix 80 g paraformaldehyde with 450 ml H2O.  
• Stir at 60 °C for 15–20 min.  
• Add droplets of 1 M NaOH until solution turns clear.  
• Add H2O to a final volume of 500 ml.  
Filter with a Nalgene
TM 
filter unit and freeze aliquots for storage (-20 °C).  
Thaw aliquots at 60 °C for use, the solution should be clear.  
 
Fixative working solution (200 ml):  
• 0.36 g NaH2PO4∙H2O  
• 3.1 g Na2HPO4∙2H2O  
• 1 g NaCl  
• 130 ml H2O  
• 20 ml glutaraldehyde 25 % in H2O, EM-grade (end 2.5 %)  
• 50 ml paraformaldehyde 16 % in H2O (end 4 %)  
Filter with a Nalgene
TM 
filter unit, adjust pH to 7.3 if necessary 
2.5.4 Immunohistochemistry 
Permeabilisation buffer: 
• 5 % BSA   2 g 
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• 0.3 % Triton-X 100 120 µl 
• Made in 1x PBS  40 ml 
Blocking solution: 
• 1 % BSA   1 g 
• 0.05 % Tween20  250 µl 
• Made in 1x PBS  500 ml 
Acid rinse solution: 
• glacial acetic acid  2 ml 
• dH2O   98 ml 
Blueing solution: 
• NH4OH   1.5 ml 
• 70 % EtOH  98.5 ml 
2.5.5 Cell lysate total protein 
RIPA Buffer (final concentration) for whole cell and tissue lysates 
• 50 mM Tris-HCl (pH 7.4) 
• 1 % NP-40 
• 0.25% Na-deoxycholate 
• 150 mM NaCl 
• 1 mM EDTA 
• 1 mM PMSF 
• 1 mM Na3VO4 
• 1 mM NaF 
• add 40 µl/ml protease inhibitor cocktail (Roche) 
 
Note: Use RIPA buffer with 0.5% Na-deoxycholate for isolation of proteins from tissue. 
2.5.6 SDS-PAGE 
Electrophoresis resolving-buffer: 
• 90.825 g (1.5 M) Tris-HCL 
• 20 ml (0.4 %) 10 % SDS 
• Adjust pH – 8.8 
Make up to 500 ml with dH20 
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Stacking-buffer: 
• 30.275 g (1 M) Tris-HCL 
• 8 ml (0.4 %) SDS 
• Adjust pH – 6.8 
Make up to 200 ml with dH20 
 
1 x SDS Sample-buffer: 
• 62.5 mM Tris-HCl (pH 6.8 at 25 0C) 
• 2 % w/v SDS 
• 10 % Glycerol 
• 50 M DTT 
• 0.01 % bromophenol blue 
 
5 x SDS Running-buffer: 
• 15.1 g (0.125 M) Tris 
• 94 g (1.250 M) Glycine 
• 50 ml 10 % SDS 
 
Make up to 1 litre with dH20 
 
Blot-buffer: 
• 2.42 g (0.02 M) Tris 
• 11.25 g (0.15 M) Glycine 
• 200 ml Methanol 
Make up to 1 litre with dH20 
 
Blocking buffer: 
• 5 g Non-fat dried milk powder 
• % or 0.05 % (v/v) Tween 20 
Make up to 1 litre with 1xPBS or 1x TBS 
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2.6  Mouse models and materials 
2.6.1 Mouse models 
 
C57BL/6      Charles River Laboratories, Sulzfeld, Germany 
TMPro/Pro   Generous gift from Mr. Prof. Dr. H. Weiler, 
Medical College of Wisconsin, USA [71] 
hPChigh      Previously established by Prof. Dr. B. Isermann’s 
lab [21] 
p66Shc  generous gift from E. Migliaccio et al., Milan, Italy                      
[63] 
2.6.2 Anesthesia 
 
sodium ketamine     Pfizer, Karlsruhe, Germany 
xylazine      Bayer, Leverkusen, Germany 
2.7  Cell culture 
2.7.1 Cells 
Conditionally immortalized rat neuronal PC12 cells were obtained from the Department of 
Neuropathology, Magdeburg. Cells were routinely grown on plates and maintained at 37°C in 
a humidified 5% CO2 incubator in a DMEM medium with 1% L-glutamine, 1 % 
penicillin/streptavidin and 10 % FBS. After pre-treatment with aPC (20 nM) or solulin (3 
µg/ml) for 1 hr, cells were treated with H2O2 (500 µM) for 1 hr [72].  
2.7.2 Media, sera, buffers and supplements 
Media, sera, buffer, supplement Company  
Foetal Bovine Serum Standard Quality PAA laboratories, Pasching, Austria 
Dulbecco´s Modiefied Eagle´s Medium Sigma-Aldrich, Taufkirchen, Germany 
1x Dulbecco's PBS + Ca2+ and Mg2+ Sigma-Aldrich, Taufkirchen, Germany 
1x HBSS with Ca2+ and Mg2+ Sigma-Aldrich, Taufkirchen, Germany 
100x Penicillin / Streptomycin PAA laboratories, Pasching, Austria 
0.05 % Trypsin and 0.02 % EDTA PAA laboratories, Pasching, Austria 
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200 mM L-Glutamine PAA laboratories, Pasching, Austria 
2.8  Oligonucleotides 
2.8.1 PCR primer pairs for RT-PCR in mice  
The following primers were purchased from Thermo Electron GmbH, Ulm, Germany. 
Primer Sequence  
D-17 loop deletion (mt-DNA) 
Fwd.: 
  5´-ACT AAT CCT AGC CCT AGC CC-3´ 
Rev.: 
  5´- AAT AAC CCT ACC CCT AGC CC-3´ 
ß-actin  
Fwd.:  
5´-GCTCCTAGCACCATGAAGATCAA-3´ 
Rev.: 
5´-AACGCAGCTCAGTAACAGTC-3´ 
TEM-1 
Fwd.: 
5´-AGC GCT GTG CAG CCC TTC AG-3´ 
Rev.: 
5´-CAC AGC TGC CAC GGA GCC AA-3´ 
2.9 Kits 
Kit Company 
BCA reagent  Thermo Scientific, Germany 
Bradford reagent Bio-Rad, München, Germany 
DAB Substrate Kit for Peroxidase  Vector Labs, Burlingame, CA, USA 
Immobilon Western Chemiluminescent 
HRP Substrate 
Merck-Millipore, Darmstadt, Germany 
ReliaPrep™ gDNA Tissue Miniprep 
System 
Promega, Heidelberg, Germany 
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2.10 Equipment 
Equipment Company 
BD Micro-Fine syringes Becton Dickinson, Heidelberg, 
Germany 
BioDoc Station Biometra, Göttingen, Germany 
Biowizard SilverLine hood Kojair, Vilppula Finland 
Blot chamber  
 
Trans-Blot Electrophoretic Transfer 
Cell, Biorad Laboratories, Germany 
Cell culture flasks and dishes Becton Dickinson, Heidelberg, 
Germany 
Cell F Imaging Software Olympus, Hamburg, Germany 
Cover slips for cell culture Paul Marienfeld GMBH & Co.KG, 
Lauda-Königshofen, Germany 
Ecocell Incubator Schnakenberg Laboratories, Bremen, 
Germany 
FEATHER microtome blades PFM, Koeln, Germany 
Harvester Tomtec, Unterschleissheim, Germany 
HERAcell 150 Incubator Thermo Scientific, Germany 
Heraeus fresco17 centrifuge Thermo Scientific, Germany 
High resolution respirometra Oroboros, Austria 
Image Pro Plus Software Media Cybernetics, Inc., Bethesda, 
MD, USA 
Immobilon-P Transfer Membrane  Merck-Millipore, Darmstadt, Germany 
LiChroCart column Merck, Darmstadt, Germany 
LiChrospher Si60 Merck, Darmstadt, Germany 
MICCRA D-1 homogenizer ART, Process and Lab Technique, 
Muellheim, Germany 
Micro 20 Centrifuge Hettich Lab Technology Tuttlingen, 
Germany 
MicroChemi 4.2 Developer Biostep, Jahndorf, Germany 
MICROM HM400 microtome MICROM International, Walldorf, 
Germany 
Nano Drop 2000c Thermo Scientific, Germany 
Olympus BX43 Microscope Olympus, Hamburg, Germany 
Olympus CK40 Microscpoe Olympus, Hamburg, Germany 
Pipettes Gilson Pipetman Gilson, Germany 
Pipettes, pipette tips and falcon tubes Sarstedt, Germany 
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pH meter 3110 WTW, Weilheim, Germany 
Power supply unit  Biorad Laboratories, Germany 
 
Rotofix 32 Centrifuge Hettich Lab Technology Tuttlingen, 
Germany 
Spectrophotometer  BIO-TEK-Instruments, Inc, Vermont, 
USA 
Spectrofluorimeter  BIO-TEK-Instruments, Inc, Vermont, 
USA 
Thermomixer Eppendorf, Germany 
Tissue flotation bath MEDITE, Burgdorf, Germany 
TSQ Quantum Discovery Max Thermo Scientific, Germany 
T3000 Thermocycler Biometra, Göttingen, Germany 
 
2.11 Interventional studies in mice  
TMPro/Pro mutant mice were maintained on a C57BL/6 background. Wild-type (WT) C57BL/6 
mice were obtained from Jackson Laboratories, Bar Harbor, ME, USA. TMPro/Pro have been 
described previously [59, 71, 73]. Age-matched female and male animals have been used (n 
= 8-10, each group). In a subset of experiments TMPro/Pro mutant mice and wt mice were daily 
injected i.p with aPC (1 mg/kg body weight) or solulin (1 mg/kg body weight, PAION GmbH) 
for 30 days. A further subgroup of TMPro/Pro mice were fed with 0.2 % cuprizone for 5 weeks 
(N = 6) [74]. Littermates were used with at least 98% of the genetic C57BL/6 background. 
Animals were housed in climate controlled rooms with a regular 12 hours day and night 
rhythm. Animal experiments were carried out in accordance with the approval of the local 
Animal Care and Use Committee of the Otto-von-Guericke-University Magdeburg. The 
approval was given by the Landesverwaltungsamt Halle/Saale, Germany).  
2.11.1 Nociception studies 
2.11.1.1 Hot plate assay: Mice were placed on a heated plate with a constant 
temperature of 50°C and time was measured until the animal showed a reaction towards 
the temperature stimulus like shaking or licking the hind paw or jumping. Mice were kept 
on the hot plate for maximum 60 seconds to avoid burnings. Analyses were done in 
triplicates taken in a 30 minutes time intervals. Minimum 8 mice were used per group. 
 
2.11.1.2 Tail flick assay: Tail retraction time was recorded after targeting the tail with a 
hot light beam. For these experiments mice were put in a restrainer and the tail was 
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exposed to the light beam for a maximum of 10 seconds to avoid burnings. Mean value 
were calculated from triplicate measurements. Minimum 8 mice were used per group. 
2.11.2 Afferent recordings in skin nerve preparation 
An in vitro skin nerve preparation was used to study the properties of mechanosensitive C 
fibers that innervate the skin of the hind paw following previously established protocols [75, 
76]. Experiments were performed on dissected skin of control wt mice and TMPro/Pro mice. 
Animals were sacrificed by CO2 inhalation, the saphenous nerve excluding the dorsal root 
ganglion was dissected with the skin of the dorsal hind paw attached and the tissue was 
mounted in an organ bath inside-up to expose the dermis. The preparation was perfused with 
an oxygen-saturated modified synthetic interstitial fluid solution containing (in mM) 123 NaCl, 
3.5 KCL, 0.7 MgSO4, 1.5 NaH2PO3 2CaCl2, 9.5 sodium gluconate, 5.5 glucose, 7.5 sucrose 
and 10 HEPES at a temperature of 32 °C and a pH 7.4. Fine filaments were teased from the 
desheathed nerve and placed on a recording electrode. Nerve fibers were classified 
according to their conduction velocities, von Frey threshold, and firing properties. Electrical 
stimulation of the nerve fiber was employed to calculate conduction velocities of individual 
nerve fibers. Fibers which conducted <1 m/s were considered to be unmyelinated C-fibers. 
The threshold for each unit was tested using calibrated von Frey filaments; the thinnest 
filament that elicited three action potentials in the time of approximately 2 seconds of 
pressing the filament on the units was taken as a threshold. Once the receptive field was 
identified using a glass rod, a computer-controlled linear stepping motor (Nanomotor 
Kleindiek Nanotechnik, Reutlingen, Germany) was used to apply standardized mechanical 
stimuli. Each fiber was tested with a series of displacement mechanical stimuli ranging from 
6 to 384 µm for both control and TMPro/Pro mice. Electrophysiological data were collected with 
a Powerlab 4.0 system (ADInstrumentsm Spechbach, Germany) and analysed off-line with 
the spike histogram extension of the software. 
 
2.11.3 Preparation of MOG35-55 –emulsion and induction of EAE in mice 
For induction of EAE in mice a 200 µl emulsion with a 1:1 ratio of myelin oligodendrocyte 
glycoprotein peptide (MOG35-55) and complete Freund´s adjuvant was prepared. It contained 
100 µl Complete Freund´s Adjuvant (CFA + 10 mg/ml Mycobacterium tuberculosis H37RA) 
and 400 µg MOG35-55 –peptide dissolved in 100 µl PBS. EAE was induced in 8 to 12 weeks 
old mice by subcutaneous immunization using the above 1:1 emulsion. Each animal received 
200 ng Pertussis toxin diluted in 100 µl PBS on days 0 and 2 post-immunization. Animals 
were assessed daily for 30 days and scored for clinical symptoms of EAE according:  
0 = healthy, no clinical symptoms 
1 = tail weakness 
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2 = definite tail paralysis and hind limb weakness 
3 = partial paralysis of hind limb 
4 = complete paralysis of hind limbs 
5 = complete paralysis of hind limbs with incontinence and partial/complete paralysis of 
forelimbs 
6 = moribund or dead 
 
Animals with 25 % loss of weight were taken out of the experiments and scored as 6.  
2.12 Animal sacrifice and tissue processing 
Mice were sacrificed at two defined time-points:  
a) 1 week after EAE onset  
b) 30 days after EAE induction 
 
Mice were anesthetized with sodium ketamine (100 mg/kg body weight i.p.) and xylazine (10 
mg/kg body weight, i.p.) , blood was taken from the inferior vena cava into a syringe pre-filled 
with 150µl anticoagulant solution (0.38% sodium citrate and 50 mM benzamidine HCl final 
concentration), and mice were perfused with PBS. The spinal cord and brain were dissected 
from all mice and further divided for specific use. For histological analyses, EM, and frozen 
sections the spinal cord was prepared from the intact cervical region of the upper spinal cord 
whereas for protein isolation the crushed lower part of the spinal cord was used. Samples 
were either fixed in 4 % formalin for histological analyses, flash frozen for protein isolation, or 
stored in Karlsson-Schultz solution for further EM analyses.  
 
2.12.1 Preparation of mitochondria 
Bain mitochondria were prepared from mice in ice-cold medium containing 250 mM sucrose, 
20 mM Tris (pH 7.4), 2 mM EGTA, and 1% (w ⁄ v) bovine serum albumin using a standard 
procedure [77]. In detail, brain tissue was homogenised and washed twice in 14 ml isolation 
medium (containing BSA). The homogenised solution was centrifuged for 5 minutes at 1000 
g (3386 h/min, 4 °C). Supernatant was further centrifuged for 10 minutes at 14000 g (12670 
h/min, 4 °C). Pellet was resuspended in 6 ml isolation medium (+BSA and 0.7 ml percoll). 
After homogenising solution was again centrifuged (10 minutes at 14000 g at 4 °C) and the 
pellet was resuspended in 7 ml isolation medium (- BSA). Finally the pellet was dissolved in 
700 µl isolation medium (- BSA) and homogenised for further purification. After the initial 
isolation, Percoll was used for purification of mitochondria from a fraction containing some 
endoplasmatic reticulum, Golgi apparatus and plasma membranes [78, 79].  
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Isolation medium (1 l, pH 7.4): 
250 mM mannitol 
1 mM EGTA 
1 mM EDTA 
0.3 % BSA 
2.12.2 Mitochondrial respiration 
Brain samples were homogenized to permeabilise plasma membranes in order to allow the 
substrates free access to the mitochondria. To this end, 20 mg of tissue were homogenized 
in a medium containing 25 mM methanol, 20 mM Tris, 1 mM EGTA and 0.3 % bovine 
albumin (pH 7.4) using a potter-elvehjem homogeniser. To enrich mitochondria the 
homogenate was centrifuged for 5 minutes at 10000 x g. Afterwards, the pellet was 
resuspended in 15 ml of a medium containing 120 mM KCl, 60 mM Tris, 35 mM mannitol, 5 
mM MgCl2, 15 mM NaCl, 10 mM KH2PO4 and 0.5 mM EGTA (pH 7.4). An aliquot of 4 ml of 
this suspension was used for the measurement of oxygen consumption at 30 °C applying 
high resolution respirometry (Orobos oxygraph, Paar Systems, Austria). Before 
measurement, the measuring system was calibrated according to the instructions of the 
manufactor. There were 2 experimental set-ups:  
a) 2 ml cell homogenate, 5 mM glutamate, 5 mM malate (basal respiration), 500 µM ADP 
(respiration with glu/mal, relating to mitochondrial respiration complex I) 
b) 2 ml cell homogenate, 10 mM succinate, 500 µM ADP (respiration with succinate, relating 
to mitochondrial respiration complex II) 
2.12.3 Incubation of mitochondria 
Mitochondria (about 0.5 mg protein/ml) were incubated in a medium containing 10 mM 
sucrose, 120 mM KCl, 20 mM Tris, 5 mM potassium phosphate, 0.5 mM EGTA and 1 mM 
free Mg2+ at pH 7.4. Oxygen consumption of mitochondria was analysed by using the method 
of high resolution respirometra (Oroboros, Austria).  
2.12.4 Cardiolipin (CL) analyses 
2.13.4.1 Extraction of Cardiolipins 
For the extraction of cardiolipins 50 ng of tetra-myristoyl-CL [(C14:0)4-CL; Avanti Polar Lipids 
Inc., Alabaster, AL] was added as internal standard to 10 µl mitochondrial suspension. For 
extraction of CL chloroform/methanol (2/1, v/v) containing 0.05% BHT as antioxidant was 
added. The lipid and aqueous phases were separated by adding 0.01 M HCl and intensive 
shaking and centrifugation. Afterwards, the lower lipid phase was collected and dried under 
nitrogen atmosphere and acidified. Ice-cold methanol (2 ml), chloroform (1 ml) and 0.1 M HCl 
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(1 ml) were added and the solution was intensively mixed. After 5 minutes of incubation on 
ice the samples were separated by the addition of chloroform (1 ml) and 0.1 M HCl (1 ml). 
The chloroform/ methanol phase was recovered as CL-containing sample. The samples were 
dried under nitrogen again and dissolved in 0.8 ml chloroform/methanol/water (50/45/5, 
v/v/v). After mixing and filtering the mixture over 0.2 µm PTFE membranes the samples were 
ready for analysis.  
2.13.4.2 HPLC-MS/MS analysis 
For measuring the molecular CL species a TSQ Quantum Discovery Max (Thermo Fisher 
Scientific GmbH, Dreieich, Germany) was used in the negative ion electrospray ionization 
(ESI) mode. The HPLC system consisted of a Surveyor MS quaternary narrow bore pump 
with integrated vacuum degasser and a Surveyor auto sampler. Auto sampler tray 
temperature was hold at 8°C. In partial loop mode a sample of 10 µl of lipid extract dissolved 
in chloroform/methanol/water (50/45/5, v/v/v) was injected and CL was separated by using a 
LiChroCart column (125 mm × 2 mm), LiChrospher Si60 (5 µm particle diameter; Merck, 
Darmstadt, Germany) and a linear gradient between solution A (chloroform) and solution B 
(methanol/water 9:1, v/v). All solutions contained 25% aqueous ammonia (0.1 ml/l). The 
gradient was as follows: 0–0.2 minutes 92% solution A, 8% solution B; 0.2–4.5 minutes 92–
30% solution A, 8–70% solution B; 4.5–6 minutes 30% solution A, 70% solution B; 6–6.5 
minutes 30–92% solution A, 70–8% solution B; 6.5–11 minutes 92% solution A, 8% solution 
B. The flow rate was 200 µl/min. Total time of analyses was 11 minutes. The eluate between 
0.3 and 6 minutes was introduced into the mass spectrometer. Nitrogen was used as the 
nebulizing gas and argon as collision gas at a pressure of 1.5 mTorr. The spray voltage was 
3.5 kV, the ion source capillary temperature was set at 375°C and the cone-voltage was 30 
V. Daughter fragments from the doubly charged parent derived from (C18:2)4-CL with m/z 
723.6 ((M−2H)2−/2) were obtained using a collision energy of 36 eV. This molecular CL 
species and the internal standard (m/z 619.6) were analysed by mass transfer reaction 
monitoring their doubly charged ions and their respective fatty acids linoleic acid m/z 279.2 
and myristic acid m/z 227.2 using the selected reaction monitoring (SRM) mode. The same 
approach was used for parent and daughter fragments of other molecular species of CL. The 
quantity of these molecular species was related to the content of (C18:2)4-CL. Oxidized CL 
[(C18:2)3monohydroxylinoleic acid-CL] was measured in the SRM mode as a transition from 
m/z 731.6 to m/z 279.2 (linoleic acid). 
2.13.4.3 Determination of protein 
The protein content of the mitochondrial suspension was measured according to the 
Bradford method [80] using bovine serum albumin as the standard. 
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2.13 Histology and immunohistochemistry 
For all histological analyses 4 µm or 10 µm (LFB) thick paraffin section from spinal cord were 
cut with the microtome. All immunhistochemical and immunofluorescence stainings were 
performed in a wet chamber. 
2.13.1 Luxol Fast Blue (LFB) stain 
The LBF stain was used to identify myelinated fibers, which stain blue, while the parenchyma 
and demyelinated areas appear white. To this end sections were dewaxed and hydrated to 
96 % ethanol and incubated in 0.2 % LFB solution over night at 58°C. The next day slides 
were washed in dH2O, differentiated repeatedly in lithium carbonate solution for 10-15 
seconds and in 70 % ethanol until there was a sharp contrast between the blue of the white-
matter and the white/colourless grey-matter of the spinal cord. After washing for 10 minutes 
in tap water the sections were transferred into cresyl violet solution for 30 minutes and then 
rinsed in dH2O. Afterwards slides were dehydrated through 96 % and 100 % ethanol for 1 
minute, moved to xylol for 10 minutes and covered with mounting medium. The myelinated 
and demyelinated areas of the spinal cord sections were analysed by a blinded investigator 
using the cellSense Dimension Imaging software. 
2.13.2  Immunofluorescence  
For immunofluorescence the spinal cord sections were dewaxed, dehydrated and then fixed 
in ice cold acetone for 1 minute. The antigens were unmasked by boiling for 30 minutes in 
antigen retrieval solution according to the manufacturer´s instructions. Further the slides 
were incubated in permeabilisation buffer (PBS + 0.3 % Triton-X 100 + 5 % BSA) for 10 
minutes, blocked for 1 h and incubated with the primary antibody over night at 4°C. The next 
day the slides were rinsed twice in PBS and the secondary fluorescein labelled anti-IgG 
antibody (3.75 μg/ml) was added for 1 hour at room temperature followed by rinsing the 
tissue sections twice in PBS. Slides were covered with DAPI containing vectashield mounting 
medium and sealed with nail polish. Slides were analysed for MAP2/nitrotyrosine co-
expression by a blinded investigator using the cellSense Dimension Imaging software. 
2.13.3 Mitotracker – 8-deHO-G staining: 
Frozen sections of spinal cord or PC12 cells, grown on cover slips, were incubated in the 
presence of 200 mM MitoTracker® Mitochondrion-Selective Probes (Invitrogen) at 37°C for 
20 minutes. After being washed with DPBS (Gibco) sections/cells were fixed with 99.5 % 
acetone (Roth) for 1 minute. Sections/cells were then incubated with 8-hydroxy-2’-
deoxyguanosine antibody (1:100 diluted in DPBS) at 4°C overnight. After washing with DPBS 
slides were incubated with FITC labeled secondary antibody (1:400 diluted in DPBS) for 1 hr 
at room-temperature. Finally slides were counterstained with vectashield containing DAPI. 
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Colocalisation of mitotracker (red) and 8-hydroxy-2’-deoxyguanosine (green) reflects 
oxidatively damaged mitochondrial DNA. Fluorescence slides were analysed for 
mitochondrial ROS, by a blinded investigator using the cellSense Dimension Imaging 
software. 
2.13.4 MitoSOX staining:  
PC12 cells were cultured on cover slips and incubated in the presence of 5 µM MitoSOX 
(Invitrogen) at 37°C for 10 minutes. After being washed with DPBS (Gibco) cells were fixed 
with 100 % methanol (Roth) for 20 minutes at -20 °C. Fixed cells were then counterstained 
with vectashield containing DAPI. Fluorescence slides were analysed for mitochondrial ROS 
by a blinded investigator using the cellSense Dimension Imaging software. 
2.13.5  Peroxidase immunohistochemistry for 8-hydroxy-2’-deoxyguanosine, 
nitrotyrosine, PGC1α and VDAC1 
Paraffin sections were dewaxed, dehydrated and then fixed in ice cold acetone for 1 minute 
and washed in PBS. Antigen-retrieval (incubation in boiling antigen unmasking solution for 30 
minutes) was performed followed by inactivation of the endogenous peroxidase activity in 
0.3% hydrogen peroxide diluted in PBS for 30 minutes at room temperature. Tissue samples 
were blocked for 1 hour incubated at room temperature and incubated with the primary 
antibody over night at 4°C. The following day slides were rinsed twice in PBS and incubated 
with the according secondary antibody (IgG-HRP). After washing twice in PBS, DAB 
substrate kit for peroxidase was added until the negative control started to develop colour. To 
stop the reaction tissue samples were immediately transferred to PBS. Counterstain was 
performed using Gill’s formula hematoxylin for 1 minute. Afterwards tissue samples were 
rinsed in water, dipped in acid rinse solution, then in water and stained in blueing solution for 
1 minute. An additional washing step followed. Tissue samples were dehydrated and fixed in 
xylol, followed by covering them in Roti Histo-Kitt II. Slides were analysed for oxidative 
damage (8-hydroxy-2’-deoxyguanosine), formation of peroxynitrite (ROS, nitrotyrosine), 
mitochondrial biogenesis (PGC1α) and outer mitochondrial membrane channel protein 
(VDAC1, reflecting mitochondrial mass) by a blinded investigator using the cellSense 
Dimension Imaging software. 
2.14 Transmission electron microscopy 
Deeply anesthetized mice were transcardially perfused with ice-cold PBS and followed by 
perfusion with fixative (2.5% glutaraldehyde, 2.5% polyvidone 25, 0.1 M sodium cacodylate 
pH 7.4). Spinal cords were dissected and washed with 0.1 M sodium cacodylate buffer (pH 
7.4). Samples were then post-fixed in the same buffer containing 2% osmium tetroxide and 
1.5% potassium ferrocyanide for 1 hour, washed in water, contrasted on bloc with uranyl 
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acetate, dehydrated using an ascending series of ethanol and embedded in glycidyl ether 
100-based resin. Ultrathin sections were cut with a Reichert Ultracut S ultramicrotome (Leica 
Microsystems, Wetzlar, Germany), contrasted with uranyl acetate and lead citrate, and were 
viewed with an EM 10 CR electron microscope (Carl Zeiss NTS, Oberkochen, Germany).  
2.15 Western blot (WB) 
Spinal cord tissue homogenates were prepared from frozen spinal cord tissues using RIPA 
buffer containing 50 mM Tris (pH7.4), 1 % NP-40, 0.5 % sodium-deoxycholate, 150 mM 
NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF supplemented with protease inhibitor cocktail 
(Roche). After centrifuging for 10 minutes at 1300 g at 4 °C the supernatants were quantified 
and protein concentrations were measured using BCA reagent (Pierce, Germany). Equal 
amount of protein samples (20 µg) were electrophoretically separated on 10 % or 12.5 % 
SDS polyacrylamide gel, transferred to PVDF membrane (Millipore) and probed with desired 
primary antibodies or primary OXPHOS antibody cocktail (Abcam, UK) at recommended 
dilutions shaking over night at 4°C. The next day the membrane was washed with PBST and 
incubated with the secondary anti-mouse IgG (1:2000) or anti-rabbit IgG (1:2000) 
horseradish peroxidase conjugated antibody. Blots were developed using the enhanced 
chemiluminiscence system (Merck-Millipore, Darmstadt, Germany). To compare and quantify 
levels of proteins, the density of each band was measured with ImageJ software. Equal 
loading was confirmed by actin or GAPDH western blot.  
2.16 Polymerase Chain Reaction (PCR) 
To visualize expression of various genes in murine spinal cord primer pairs listed under 2.9.1 
were used. PCRs with a final volume of 25 µl were setup as followed: 
1.0 µl undiluted cDNA 
5.0 µl 5x Green GoTaq Flexi Buffer 
2.5 µl 25 mM MgCl2 
0.2 µl 25 mM dNTPs 
0.5 µl 10 nM forward primer 
0.5 µl 10 nM reverse primer 
15.2 µl sterile ddH2O 
0.1 µl GoTaq Flexi DNA Polymerase  
 
PCRs were run on the Biometra T3000 Thermocycler under conditions optimized for each 
primer pair.  
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To visualize the D17-loop deletion of mitochondrial DNA total DNA isolated from mouse brain 
was used and the primer pair listed under 2.9.1. 
 
Gel electrophoresis 
Amplified DNA was detected by running 10 µl of the reaction on a 1 % TBE agarose gel 
containing ethidium bromide. To prepare a 1 % gel, 100 ml of 0.5 x TBE buffer were added 
to a 250 ml bottle containing 1 g of agarose. The agarose was heated in a microwave to 
boiling at which point it melted readily. Ethidium bromide was added to a final concentration 
of 0.5 µg/µl. The agarose was then poured into a gel electrophoresis box with a well comb 
large enough to accommodate both, sample size and number. After the gel cooled down, 0.5 
x TBE buffer was added to the buffer chambers and the comb removed. 
The DNA samples were then loaded into the wells. A marker with known molecular weight 
was loaded alongside the DNA in separate lane. A power supply was then connected to the 
electrophoresis box delivering a current of 100 volts. The DNA migrated down through the 
gel toward the anode because of its negative charge. The separation of the DNA was 
documented by taking a photo of the gel under a BioDoc station. Expression was normalized 
to β-actin. Reactions lacking reverse transcriptase served as controls. 
2.17 Amplification of mitochondrial DNA by PCR 
To visualize the expression of mitochondrial DNA of murine brain total DNA from mouse 
brain tissue was isolated. 
2.17.1 Total DNA isolation from tissue 
Total DNA (DNA) was isolated following instructions of ReliaPrep™ gDNA Tissue Miniprep 
System (Promega). The frozen brain tissue (25 mg) was homogenized by using a chilled 
mortar and pestle. To the powder-like solution 160 µl PBS and 20 µl Proteinase K were 
added. Next, 200 µl cell lysis buffer (all buffers are provided with the kit) was added to each 
sample and vortexed for at least 10 seconds. Afterwards, samples were incubated at 56 °C 
for up to two hours shaking. Then, 20 µl RNase A solution was added, mixed and vortexed 
for 10 seconds and placed at 56°C for 10 minutes. After adding 250 µl of binding buffer tubes 
were mixed and vortexed again. Then, a binding column was placed inside a collection tube. 
After centrifuging for 1 minute at maximum speed the liquid portion was discarded and the 
column was washed twice. Finally the eluant was collected by adding 200 µl nuclease-free 
water and centrifugation at maximum speed for 1 minute. Samples were stored at -20 °C 
until analyses. 
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2.18 Statistical analysis 
All ex vivo experiments were performed at least in triplicates. The data are summarized as 
the mean ± s.e.m. (standard error of the mean). Number of damaged myelin/axon per image 
branching mitochondria were counted from at least 10 images per mouse. Data are shown 
as arbitrary units. Statistical analyses were performed using Student’s t test or Kruskal-Wallis 
test (as indicated in the figure legend or in the text). StatistiXL (http://www.statistixl.com) and 
Prism Version 5 software (GraphPad) was used for statistical analyses. Statistical 
significance was accepted at the P < 0.05 level. 
40 
 
3 Results 
3.1 Thrombomodulin-mediated protein C activation maintains neuronal 
function and myelin structure 
To determine the consequence of impaired TM-mediated PC activation for diabetic 
neuropathy we used mice with severely impaired PC activation secondary to a point mutation 
in TM (Glu404Pro, TMPro/Pro mice) [71]. Unexpectedly, the nociceptive sensitivity was already 
reduced in non-diabetic TMPro/Pro mice when compared to non-diabetic wt control mice 
(matched for age, sex, and background) (Fig. 3.1.1 A-B). This uncovers a previously 
unknown phenotype in mice with reduced anticoagulant capacity and impaired PC activation 
due to a point mutation in TM. Following 26 weeks of persistent hyperglycaemia the 
nociceptive sensitivity decreased further in the hot-plate and the tail flick assay (increased 
latency) in TMPro/Pro, as reflected by an increased reaction time compared to non-diabetic 
TMPro/Pro and diabetic wt mice. However, the difference between non-diabetic and diabetic 
mice was comparable in wt (Δt = 7,0 sec. and Δt = 1,7 sec. for the hot plate and the tail-flick 
assay, respectively) and TMPro/Pro mice (Δt = 5,6 sec. and Δt = 1,2 sec.; P<0,05 for both 
comparisons, Fig. 3.1.1 A, B). Thus, in mice with impaired TM-dependent PC activation 
nociceptive sensitivity is reduced already in the absence of persistent hyperglycaemia. 
Superimposed hyperglycaemia has an additional additive effect in TMPro/Pro mice on 
nociceptive sensitivity, which, however, is comparable to the hyperglycaemia dependent 
effect in wt diabetic mice. This indicates that loss of TM function does not aggravate 
hyperglycaemia induced impairment of nociceptive sensitivity, but constitutes and additive 
factor diminishing nociceptive sensitivity independent of hyperglycaemia induced nociceptive 
dysfunction.  
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Fig. 3.1.1: Impaired nociception in TMPro/Pro mice  
A-B: Nociception is impaired in TMPro/Pro mice compared to background-, age- and sex-matched wt mice. 
The latency in the hot plate (A) and tail flick (B) assay is increased in TMPro/Pro as compared to wt mice. 
Persistent hyperglycaemia impairs nociception in wt and TMPro/Pro mice to the same extend, as indicted by a 
comparable delta of the latency in the hot-plate assay (A). In the tail-flick (B) assay no differences were 
visible. Bar graphs summarise results of at least three repeat measurements in 10 (A, B,) different mice per 
group. *P < 0.05; **P < 0.01; Student’s t-test. 
 
In order to characterise the impaired nociception in non-diabetic TMPro/Pro mice we analysed 
firing properties of peripheral afferent fibres. Skin-nerve preparation of the saphenous nerve 
from non-diabetic wt and TMPro/Pro mice were prepared and stimulated. Intriguingly, stimulus-
response functions of various fibres, including C-fibers (Fig. 3.1.2 ), showed no difference 
between wt and TMPro/Pro mice, indicating that the impaired nociception observed in TMPro/Pro 
mice is not caused by an impaired function of the peripheral nerve and may be related to a 
defect of second-order neurons in the spinal cord. 
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Fig. 3.1.2: Peripheral nerve function is not impaired in TMPro/Pro mice 
The stimulus response of peripheral nerves is similar in TMPro/Pro and wt mice. Electrophysical analyses of 
skin-nerve preparation obtained from paws of healthy wt (red, n= 4) and healthy TMPro/Pro mice (blue, n = 4). 
Firing rates of C-mechanociceptors (C-fibers) were evoked by application of increasing, 10 seconds lasting 
pressure via a nanomotor (expressed in terms of displacement). 
Ultrastructural analyses of the upper spinal cord using TEM revealed an altered morphology 
in TMPro/Pro mice. In contrast to an intact dense axonal arrangement with dark multi-layer 
myelin structures of spinal cord axons in wt control mice (Fig. 3.1.3) loosening of the myelin 
sheath and a pale axoplasm devoid of organelles was readily visible in spinal cord axons of 
TMPro/Pro mice (Fig. 3.1.3). Of note, healthy TMPro/Pro mice lack signs of spontaneous 
inflammation [71, 81]. These data suggest that the impaired nociception in TMPro/Pro mice is 
not caused by a defect of the peripheral nerves, but linked with dysfunctional neurons in the 
CNS independent of spontaneous inflammation.  
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Fig. 3.1.3: Impaired myelin structure in TMPro/Pro mice 
Myelination defect in the upper spinal cord of TMPro/Pro mice. TEM images of mouse spinal cord showing 
loosening of the myelin sheath [arrow heads] and pale axoplasm devoid of organelles [asterix] in TMPro/Pro 
mice compared to wt mice. Scale bars: 500 nm. Bar graphs summarising results obtained from 3 mice per 
group. ** P < 0.01; Student’s t-test.  
 
 
3.2 Loss of endogenous PC activation increases markers of oxidative stress 
As neurons are sensitive to ROS (reactive oxygen species) induced damage and as aPC has 
been shown to reduce ROS generation [19, 82-84] we next analysed markers reflecting ROS 
generation in spinal cord (immunohistochemistry) and brain (immunoblotting) tissue. 
Nitrotyrosine (ONOO-), a marker of peroxynitrite formation, and 8-hydroxy-2’-
deoxyguanosine, reflecting ROS induced DNA-damage, were both increased in TMPro/Pro 
mice as compared to wt mice (Fig. 3.2.1 A-C).  
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Fig. 3.2.1: Increased oxidative stress markers in the CNS of mice with impaired endogenous PC 
activation  
A: Representative immunohistochemical images (left) and bar graphs (right) showing an increased staining 
intensity of nitrotyrosine in TMPro/Pro mice as compared to wt mice. B: Representative immune-blots (bottom) 
and bar graphs (top) showing nitrotyrosine levels in mouse spinal cord tissue samples. Bar graphs 
summarise semi-quantitative results obtained from eight different mice per group. C: Representative 
immunohistochemical images (left) and bar graphs (right) showing an increased staining intensity of 8-
hydroxy-2’-deoxyguanosine in mouse spinal cord in TMPro/Pro mice as compared to wt mice. Brown, 
nitrotyrosine (A) or 8-hydroxy-2’-deoxyguanosine (C) positive cells detected by horseradish peroxidase-3,3´-
diaminobenzidine reaction; blue, haematoxylin counterstain. Black squares (A, C) indicate areas shown at 
higher magnification in the inset in the right corner (white frame). Scale bars (A, C): 20 µm. N = 8. *P < 0.05; 
**P < 0.01; Student´s t-test. 
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To determine whether impaired PC activation increases mitochondrial ROS generation we 
determined the co-localization of 8-hydroxy-2’-deoxyguanosine with mitochondria using 
immunofluorescence analyses. In TMPro/Pro mice co-localization 8-hydroxy-2’-deoxyguanosine 
with mitochondria in spinal cord tissue was increased as compared to wt mice (Fig. 3.2.2), 
suggesting that in mice with defective PC-activation mitochondrial ROS generation is 
increased in the CNS.  
 
Fig. 3.2.2: increased mitochondrial ROS in TMPro/Pro mice 
Representative co-immunofluorescence images (left) and summarising bar graphs (right) showing 
mitotracker (red, mitochondrial ROS) and 8-hydroxy-2’-deoxyguanosine (green) staining in mouse spinal 
cord. In TMPro/Pro mice, co-localization (yellow, Icorr) is increased compared to wt mice. Blue, counterstain 
with DAPI. Scale bars: 20 µm. *P < 0.05; **P < 0.01; Student’s t-test. 
3.3 Altered mitochondrial morphology in TMPro/Pro mice  
To explore potential causes of impaired mitochondrial function and increased mitochondrial 
ROS generation in the CNS of TMPro/Pro mice we next determined expression of porin 
(VDAC1), a mitochondrial marker-protein reflecting mitochondrial mass, and PGC1α, a 
transcription factor reflecting mitochondrial biogenesis [85-87]. Expression of both marker 
proteins was not altered in the spinal cord of TMPro/Pro mice as compared to wt mice (Fig. 
3.3.1 A-D), indicating that neither mitochondrial mass nor mitochondrial biogenesis is 
impaired in TMPro/Pro mice.  
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Fig. 3.3.1: mitochondrial mass and biogenesis are not impaired in TMPro/Pro mice  
A-D: Expression of porin (A, B), reflecting mitochondrial mass, and PGC1α (C, D), reflecting mitochondrial 
biogenesis, in the upper spinal cord does not differ in wt and TMPro/Pro mice. Representative 
immunohistochemical images of porin (A, left) and PGC1α (C, left), bar graphs reflecting the frequency of 
positively stained cells (A, C, right), and representative immuno-blots (B, D, bottom) and bar graphs (B, D, 
top) summarising porin (B) or PGC1α (D) expression in mouse spinal cord tissue samples. Brown, porin (A) 
or PGC1α (C) positive cells detected by horseradish peroxidase-3,3´-diaminobenzidine reaction; blue, 
hematoxylin counterstain. Scale bars: 20 µm (A, C). Bar graphs represent the mean ± SEM of 6 (A-D) mice 
per group. 
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We next analysed mitochondria morphology using TEM. Total mitochondria from brain tissue 
of TMPro/Pro mice showed frequently a distorted or “branching” morphology as compared to 
mitochondria from wt mice (Fig. 3.3.2). Hence, increased mitochondrial ROS generation in 
the CNS of TMPro/Pro mice is associated with an altered mitochondrial function, but not with an 
altered mitochondrial number or biogenesis, consistent with a functional defect of 
mitochondria in the CNS of TMPro/Pro mice. 
  
Fig. 3.3.2: Altered mitochondrial morphology in TMPro/Pro mice 
Left: TEM images of mouse spinal cord showing increased mitochondrial branching (red circle) in TMPro/Pro 
mice as compared to wt mice. Scale bar: 500 nm. Right: Bar graphs represent the mean ± SEM of 3 mice 
per group; ** P < 0.01; Student´s t-test. 
3.4 Impaired mitochondrial respiration and increased cardiolipin oxidation in 
TMPro/Pro mice  
To determine mitochondrial function we analysed mitochondrial respiration in isolated brain 
mitochondria from wt and TMPro/Pro mice. Mitochondrial oxygen consumption was reduced in 
TMPro/Pro derived mitochondria as compared to wt derived mitochondria, both following 
addition of glutamate and malate (probing for complex I/III activity) or succinate (probing for 
complex II/III) as substrates (Fig. 3.4.1 A). Thus, mitochondrial function is impaired in 
TMPro/Pro derived mitochondria, and this defect appears to include an impaired function of 
complex III to V. We next determined levels of complexes I to V of the respiration chain using 
marker proteins for each complex. All marker proteins were either tentatively, but not 
significantly (NDUFB8, for complex I; complex IV subunit I) or significantly (marker proteins 
SDHB, UQCRC2 and ATP5α, reflecting complex II, complex III core protein and complex V 
alpha subunit) increased (Fig. 3.4.1 B). The increased expression of these markers protein 
argues against impaired activity of the respiratory chain due to a complex deficiency and 
indicates a functional defect.  
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Fig. 3.4.1: Impaired mitochondrial respiration in TMPro/Pro mice  
A: Oxygen consumption in TMPro/Pro derived mitochondria is reduced as compared to wt mitochondria. 
Mitochondria were isolated from the upper spinal cord and oxygen consumption was determined following 
stimulation of mitochondria with either 5 mM glutamate + 5 mM malate (Glu/Mal) or 10 mM succhinate 
(Succ). B: Altered expression of mitochondrial respiratory chain marker proteins in upper spinal cord protein 
extracts of TMPro/Pro mice as compared to wt controls. Representative immune-blots (bottom) and bar graphs 
(top) reflecting relative expression (in %, relative to wt control) of the CI subunit NDFUFB8 (CI), CII-30kDa 
(CII), CIII-core protein 2 (CIII), CIV subunit I (CIV), and CV alpha subunit (CV). *P < 0.05; *P < 0.01; 
Student‘s t-test. 
We next analysed cardiolipins in wt and TMPro/Pro mice as the function of the mitochondrial 
respiratory chain depends in part on the composition of cardiolipins (CL) [88]. Cardiolipins 
were isolated from mouse brain derived mitochondria and their fatty acid composition was 
analysed probing for the 17 most frequent CL-associated fatty acid species by HPLC/MS. 
Intriguingly, while the concentration of linoleic acid (C18:2) was increased, the concentration 
of palmitic acid (C16:0) was significantly and that of oleic acid (C18:1) slightly (but non-
significantly) reduced in TMPro/Pro mice as compared to wt control mice (Fig 3.4.2 A). All other 
fatty acids showed no significant changes (Fig. 3.4.2 C). C18:2 is particular sensitive to 
oxidation and oxidised CLs impair the mitochondrial respiratory chain function [88-90]. 
Accordingly, we observed an increased oxidation of (C18:2)4 cardiolipins in TMPro/Pro derived 
mitochondria as compared to wt mitochondria (Fig. 3.4.2 B).  
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Fig. 3.4.2 A-C: Increased cardiolipin oxidation in TMPro/Pro mice 
Analyses of cardiolipins (CL): the fatty acid composition of CL-species obtained from TMPro/Pro derived 
mitochondria is altered, with an increase of C18:2 and a reduction of C16:0 fatty acids, when compared with 
CL obtained from wt mitochondrial (C). The frequency of oxidised CL (C18:2) is increased in TMPro/Pro 
derived mitochondria as compared to wt controls (D). E: Mitochondrial cardiolipin of wt and TMPro/Pro mice. 
Representative bar graphs show concentrations of incoorporated fatty acids into mitochondrial cardiolipins in 
mouse brain. Bar graphs summarise results obtained from six different mice in each group. *P < 0.05; 
Student‘s t-test. 
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As oxidation of CL is not only associated with an impaired activity of the mitochondrial 
respiratory chain, but also with an impaired stability of mitochondrial DNA [91] we analysed 
the D17-loop deletion, reflecting mitochondrial DNA damage. The D17-loop deletion was 
more frequent in TMPro/Pro derived brain mitochondria as compared to wt mitochondria (Fig. 
3.4.3). Taken together, these results establish the CL composition, CL oxidation, and 
mitochondrial function is impaired in mitochondria derived from neuronal tissues of TMPro/Pro 
mice.  
 
Fig. 3.4.3: Mitochondrial DNA damage, indicated by enhanced D17-loop deletion, is increased in TMPro/Pro 
derived mitochondria as compared to wt controls. Bar graphs summarising results obtained from six different 
mice in each group; *P < 0.05; Student‘s t-test. 
3.5 aPC reduces mitochondrial ROS in neuronal cells in vitro 
Considering the low level of endogenous aPC generation in TMPro/Pro mice and the 
established neuro-protective effects of aPC we next explored whether aPC cell-
autonomously reduces mitochondrial ROS generation in rat neuronal PC12 cells. Exposure 
of PC12 cells to H2O2 time-dependently induces mitochondrial ROS generation (Fig. 3.5.1 A-
B), with a significant induction 15 min and maximal levels 60 min after addition of H2O2. PC12 
were left untreated (PBS control) or treated with aPC (20 nM; 1 h pre-incubation), stimulated 
with H2O2, and analysed after 15 and 60 min. Pre-treatment with aPC reduced mitochondrial 
ROS generation in neuronal PC12 cells at both time-points (Fig. 3.5.1 C-D). These findings 
demonstrate that aPC cell-autonomously restricts mitochondrial ROS production in neuronal 
cells.  
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Fig. 3.5.1: aPC normalises mitochondrial ROS production in neuronal cells in vitro 
A: Mitochondrial ROS production upon H2O2 stimulation. Representative images show immunofluorescence 
staining of rat neuronal PC12 cells. Red, mitotracker (mitochondrial marker); green, 8-hydroxy-2’-
deoxyguanosine (ROS marker); yellow, merge; blue, nuclear DAPI counterstain; scale bars: 20µm. B: H2O2 
stimulation increased ROS production in rat neuronal cells. Bar graphs summarising obtained results from 3 
independent experiments. **P < 0.01, Students t-test. C-D: Rat neuronal PC12 cells were exposed to H2O2 
(500 µM, 1hr) and cell were stained after indicated time-intervals with MitoSOX (red), detecting 
mitochondrial ROS (counterstain with DAPI, blue). Pre-treatment with aPC (20 nM) reduces mitochondrial 
ROS production. Representative fluorescent images (C) and bar graph (D) summarising results of 3 
independent experiments; scale bars: 20 µm; *P < 0.05; **P < 0.01; Student’s t-test.  
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3.6 aPC restores ROS generation, nociception and stabilises mitochondrial 
DNA in TMPro/Pro mice 
To determine whether restoring aPC can correct for the defects observed in TMPro/Pro mice we 
next analysed TMPro/Pro x hPChigh mice and TMPro/Pro mice treated with aPC. Genetically 
restoring defective PC-activation in TMPro/Pro mice by breeding with hPChigh mice reduced 
ROS production, as reflected by reduced peroxynitrite and 8-oxo-dG staining, in the CNS 
(Fig. 3.6.1 A-D). This suggests that the neuronal defects observed in mice with impaired TM-
dependent PC activation may be reversible.  
 
 
Fig. 3.6.1: aPC normalises ROS-generation 
A-D: Representative images of immunohistochemically stained upper spinal cord sections (A, C) and bar 
graphs summarising results of eight mice per group (B, D). Restoring aPC in mice reduces nitrotyrosine (A, 
B) and 8-hydroxy-2’-deoxyguanosine (C, D) levels in TMPro/Pro x hPChigh mice. Brown, nitrotyrosine (A) or 8-
hydroxy-2’-deoxyguanosine (D) positive cells detected by horseradish peroxidase-3,3´-diaminobenzidine 
reaction; blue, haematoxylin counterstain. Scale bars: 20 µm; **P < 0.01; Student’s t-test.  
 
Next, we wanted to determine whether exogenous application of aPC is sufficient to restore 
impaired nociception and mitochondrial stability in TMPro/Pro mice, so we treated TMPro/Pro mice 
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with aPC (1 mg/kg body weight intraperitoneally, for 4 weeks). Pharmacological intervention 
aiming to restore defective aPC-generation in TMPro/Pro mice was sufficient to normalise 
nociception, as reflected by a reduction of the latencies in the hot-plate and a faster reaction 
time in tail-flick assay (Fig. 3.6.2 A, B). Further, exogenous aPC administration was sufficient 
to stabilise mitochondrial DNA, as reflected by less frequent D17-loop deletions compared to 
TMPro/Pro mice (Fig. 3.6.2 C-D). These results establish that impairment of TM-dependent PC 
activation, as observed in individuals with vascular or inflammatory diseases, is sufficient to 
cause neuronal dysfunction. Importantly, the neuronal defect induced by defective TM-
mediated PC activation is reversible upon pharmacological substitution of aPC. 
  
 
Fig. 3.6.2 A-D: aPC normalises nociception and reconstituted mitochondrial stability in TMPro/Pro mice 
A-B: Nociception (hot-plate assay, E; tail flick assay, F) is restored in TMPro/Pro x hPChigh mice. Bar graphs 
summarise results of at least 8 mice per group (A, C) or of three repeat measurements in at least 8 (E-F) 
different mice per group. Spotted line shows baseline level (100 %) of reaction time. *P < 0.05; **P < 0.01; 
Student’s t-test. C-D: Mitochondrial DNA damage, indicated by reduced D17-loop deletion, is ameliorated in 
TMPro/Pro + aPC mice derived mitochondria as compared to TMPro/Pro mice. Bar graphs summarising results 
obtained from six different mice in each group; *P < 0.05; Student‘s t-test.
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Taken together, these data establish that the basal impaired nociception in aPC-deficient  
mice is not caused by a defect of the peripheral nerves, but linked with dysfunctional neurons 
in the CNS, caused by increased mitochondrial ROS production and altered mitochondrial 
function in neuronal cells. These results proved a hitherto unknown basal phenotype showing 
that impairment of TM-dependent PC activation, as observed in individuals with vascular or 
inflammatory diseases, is sufficient to cause neuronal dysfunction. Importantly, restoring the 
defective PC-activation ameliorated impaired neuronal function, establishing that the basal 
neuronal defect induced by defective TM-dependent PC activation is therapeutically 
amendable.  
 
 
The above data uncover a new physiological function of the TM-dependent PC-activation for 
neuronal function and proper myelination in the CNS. This defect did not impair the function 
of peripheral nerves and did not accelerate – beyond the additive effect – peripheral 
neuropathy. However, we speculated that the impaired neuronal function and myelination 
within the CNS would predispose to demyelinating diseases of the CNS. 
 
3.7 Loss of thrombomodulin-dependent protein C activation aggravates EAE 
To determine the relevance of TM-dependent endogenous PC activation we used TMPro/Pro 
mice. The disease onset was virtually identical in TMPro/Pro and wild-type (wt) mice after 
induction of EAE (around day 11). However, the disease severity was markedly aggravated 
in TMPro/Pro EAE mice, being significantly worse from day 14 onwards until the end of the 
observation period (day 30) (Fig. 3.7.1 A). Average EAE scores were calculated for each day 
and summed for the entire experiment to yield a Cumulative Disease Index (CDI), 
representing total disease load. WT mice had a CDI of 27.83±0.21, whereas TMPro/Pro mice 
demonstrated a significantly higher CDI of 52.95±0.23 (Fig.3.7.1 B). 
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Fig. 3.7.1: Impaired endogenous PC activation aggravates EAE 
A: Severity of EAE, based on a clinical score, in wt and TMPro/Pro mice. Clinical disease score was 
aggravated in TMPro/Pro mice compared to wt mice. B: The cumulative disease index for EAE TMPro/Pro mice 
was significantly higher than EAE wt mice. (N = 8) *P < 0.05; Student´s t-test. 
 
 
Histological analyses of cervical spinal cord using Luxol-Fast-Blue stained sections revealed 
no obvious difference between control wt and TMPro/Pro control mice (Fig. 3.7.2). However, 
analyses of tissue samples obtained from mice 4 weeks after disease induction revealed an 
aggravated reduction of myelin in TMPro/Pro EAE as compared to wt EAE mice (Fig 3.7.2).  
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3.7.2: Aggravated demyelination in EAE TMPro/Pro mice 
left: Myelin staining of mouse spinal cord by using Luxol-Fast-Blue (LFB). No difference was apparent at 
baseline (left), while demyelination was aggravated after 4 weeks EAE in TMPro/Pro EAE mice compared to wt 
EAE mice. Scale bars: 200 µm. right: Bar graphs showing counted demyelinated axons in LFB stained 
images (10 axons, N = 5), ** P < 0.01; Student´s t-test. 
We next conducted ultrastructural analyses using TEM. In EAE wt mice, loosening of the 
myelin sheath or complete demyelination [note: arrow heads; figure legends] and pale 
axoplasm devoid of organelles [asterix] were visible (Fig. 3.7.3). These ultrastructural 
changes were aggravated in TMPro/Pro EAE mice (Fig. 3.7.3).  
 
   
Fig. 3.7.3: Impaired myelin structure in EAE TMPro/Pro mice 
left: TEM images of mouse spinal cord showed loosening of the myelin sheath or complete demyelination 
[arrow heads] and pale axoplasm devoid of organelles [asterix] in EAE mice. These ultrastructural changes 
were aggravated in TMPro/Pro EAE mice. right: Bar graphs summarising frequency of ruptured nerve fibers. 
Scale bars: 500 nm, N = 3. **P < 0.01; Student´s t-test. 
Taken together, based on a phenotypic and on histological analyses loss of endogenous PC 
activation aggravates EAE severity and associated neuronal demyelination. 
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3.8 Loss of endogenous PC activation increases markers of oxidative stress 
Enhanced ROS generation contributes to neuro-degenerative diseases, including EAE. To 
determine whether impaired TM-dependent PC activation results in increased oxidative 
stress we analysed markers of ROS-generation, ONOO- and 8-oxo-dG. Using 
immunohistochemical analyses of spinal cord sections both markers were increased in EAE 
mice at 1 week after disease onset and at 4 weeks after disease induction (Fig. 3.8.1 A-B, D-
E). The staining intensity was markedly increased in TMPro/Pro mice at both time-points (Fig. 
3.8.1 A-B, D-E), indicating enhanced ROS generation in mice with impaired PC activation.  
Next, we used immunoblot analyses of spinal cord protein lysates to confirm the increased 
expression of ONOO-. We found a corresponding expression pattern of ONOO- expression in 
EAE mice as shown in the immunohistochemical staining (Fig. 3.8.1 C). ONOO- was 
significantly increased in EAE mice in both wt and TMPro/Pro mice after 1 week of disease 
onset and 4 weeks of disease induction. In TMPro/Pro mice ONOO- expression was even 
aggravated compared to wt mice (Fig. 3.8.1 C). These data demonstrate that endogenously 
impaired PC activation enhances ROS during EAE disease course.  
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Fig. 3.8.1: Loss of endogenous PC activation increases markers of oxidative stress 
A-B: Representative images (A) and bar graphs (B) showing immunohistochemical staining of mouse spinal 
cord. Nitrotyrosine is strongly expressed in EAE diseased mice after one week and expression is further 
increased after four weeks of EAE in both, wt and TMPro/Pro mice. Brown, nitrotyrosine positive cells detected 
by horseradish peroxidase-3, 3´-diaminobenzidine reaction; blue, hematoxylin counterstain. Scale bars: 20 
µm, N = 8. C: Representative western blots (bottom) and bar graphs (top) showing nitrotyrosine expression 
in mouse spinal cord tissue samples. Bar graphs summarise results obtained from eight different mice in 
each group. * P < 0.05, ** P < 0.01, Students t-test. D-E: Immunohistochemical staining for 8-hydroxy-2’-
deoxyguanosine of mouse spinal cord. In EAE diseased mice, 8-hydroxy-2’-deoxyguanosine staining was 
aggravated after 4 weeks compared 1 week EAE in both groups, wt and TMPro/Pro mice. In TMPro/Pro mice 
staining intensity was increased compared to wt mice. Brown, 8-hydroxy-2’-deoxyguanosine positive cells 
detected by horseradish peroxidase-3, 3´-diaminobenzidine reaction; blue, hematoxylin counterstain. Scale 
bars: 20 µm, N = 8. * P < 0.05; ** P < 0.01; Student´s t-test. 
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3.9 Mitochondrial defect in TMPro/Pro mice  
To further evaluate whether the mitochondrial defect in TMPro/Pro mice is aggravated during 
the EAE course we determined expression of the mitochondrial marker porin (VDAC1). After 
1 week of EAE onset porin expression levels were slightly but not significantly reduced in the 
spinal cord of TMPro/Pro mice as compared to wt mice (Fig. 3.9.1 A, B). But the expression was 
significantly decreased after 4 weeks of EAE induction in TMPro/Pro mice compared to wt mice. 
Both in wt and TMPro/Pro mice porin levels declined during the course of EAE. Immunoblot 
analyses of spinal cord lysates confirmed the decrease of porin expression in both wt and 
TMPro/Pro diseased mice (Fig. 3.9.1 C). After 4 weeks of EAE induction there was significantly 
less porin expression detectable in TMPro/Pro compared to wt EAE mice (Fig. 3.9.1 C). Next, 
we determined expression of the transcription factor PGC1α, which reflects mitochondrial 
biogenesis. A slight bot non-significant reduction became apparent in diseased TMPro/Pro mice 
at 1 week after disease onset which became significantly after 4 weeks of EAE induction 
(Fig. 3.9.1 D, E). Again western blot analyses confirmed the reduction of PGC1α during 
disease course in both wt and TMPro/Pro mice (Fig. 3.9.1 F). 
Hence, mitochondrial ROS-generation precedes a defect in mitochondrial biogenesis in EAE 
TMPro/Pro mice, indicating that loss of TM-dependent PC generation impairs primarily 
mitochondrial function and not mitochondrial biogenesis. However, during the EAE 
progression and the associated ROS generation mitochondrial biogenesis becomes 
eventually impaired.  
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Fig. 3.9.1: Acquired mitochondrial deficiency in TMPro/Pro mice 
A: Representative images showing immunohistochemical staining of mouse spinal cord. Four weeks after 
EAE onset, porin expression is decreased in EAE diseased mice in wt and TMPro/Pro mice. Brown, porin 
positive cells detected by horseradish peroxidase-3,3´-diaminobenzidine reaction; blue, hematoxylin 
counterstain. Scale bars: 20 µm. B: Bar graphs summarising the counting of porin positive cells from 
immunohistochemical staining. (N = 6). **P < 0.01; Student´s t-test. C: Representative western blots 
(bottom) and bar graphs (top) showing porin expression in mouse spinal cord tissue samples. Bar graphs 
summarize results obtained from six different mice in each group. *P < 0.05, Students t-test. D: 
Immunohistochemical staining for PGC1α of mouse spinal cord. PGC1α expression was decreased four 
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weeks after EAE onset in both groups, wt and TMPro/Pro mice. Brown, PGC1α positive cells detected by 
horseradish peroxidase-3,3´-diaminobenzidine reaction; blue, hematoxylin counterstain. Scale bars: 20 µm. 
E: Bar graphs summarising the results of counting PGC1α positive cells. (N = 6) *P < 0.05, Students t-test. 
F: Representative western blots (bottom) and bar graphs (top) showing PGC1α expression in mouse spinal 
cord tissue samples. Bar graphs summarise results obtained from six different mice in each group. *P < 
0.05; **P < 0.01; Student´s t-test. 
 
3.10 Soluble TM is superior compared to p66Shc-inhibtion or aPC-treatment in 
EAE TMPro/Pro mice 
To address potential mechanisms aggravating EAE in TMPro/Pro mice various in vivo 
interventions were conducted. First, we tested the potential impact of impaired PC activation 
in TMPro/Pro mice. To this end TMPro/Pro mice were crossed with hPChigh mice. The latter 
express a mutant human PC, which can be efficiently activated by thrombin even in the 
absence of functional TM, resulting in increased plasma levels of aPC [21]. The initial 
disease course did not differ between TMPro/Pro and TMPro/Pro x hPChigh mice, e.g. the disease 
onset and the disease severity were virtually identical until day 19 (Fig. 3.10.1 A). However, 
after day 19 the disease severity was improved in TMPro/Pro x hPChigh mice compared to 
TMPro/Pro mice (Fig. 3.10.1 A), corroborating results in wt EAE mice treated intravenously with 
aPC [44]. Luxol-Fast-Blue staining of spinal cord sections showed a decreased 
demyelination in TMPro/Pro x hPChigh EAE mice compared to TMPro/Pro EAE mice 1 week after 
disease onset and 4 weeks after EAE induction (Fig. 3.10.1 B). Thus, aPC only partially 
corrects for impaired TM function in the context of EAE. In agreement with an antioxidant 
effect of aPC indices of excess ROS generation (ONOO-, 8-oxo-dG) were markedly reduced 
in TMPro/Pro x hPChigh mice (Fig. 3.10.2 A, B).  
Next, we evaluated EAE and ROS-generation within the CNS in TMPro/Pro mice with 
genetically superimposed p66Shc deficiency (TMPro/Pro x p66Shc-/-) [19]. Genetically inactivation 
of the redox-protein p66Shc has been shown to compensate for impaired TM function in 
TMPro/Pro mice in the context of diabetic nephropathy, normalising indices of diabetic 
nephropathy and renal ROS markers. In the context of EAE genetically superimposed p66Shc 
deficiency (TMPro/Pro x p66Shc mice) did not delay the disease onset, but improved the clinical 
EAE score throughout the entire observation period and diminishes tissue injury (Fig. 3.10 
A). Again Luxol-Fast-Blue staining of spinal cord sections showed a decreased 
demyelination in TMPro/Pro x p66Shc EAE mice compared to TMPro/Pro EAE mice 1 week after 
disease onset and 4 weeks after EAE induction (Fig. 3.10.1 B). The reduction of oxidative 
stress markers (nitrotyrosine and 8-oxo-dG) was likewise more pronounced in TMPro/Pro x 
p66Shc mice than in TMPro/Pro x hPChigh mice (Fig. 3.10.1 A, B). Hence, p66Shc deficiency is 
superior to restoring aPC levels in regard to EAE in TMPro/Pro mice, indicating that TM 
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mediates a protective effect in the context of EAE, which may be partially independent of PC 
activation.  
Soluble forms of TM have been evaluated in pre-clinical and clinical studies as an alternative 
mean to restore TM-dependent PC-activation as well as other potential cytoprotective effects 
of TM [49]. We used solulin, a soluble TM variant [49], to evaluate the therapeutic value of 
this approach in EAE. Strikingly, treatment of EAE TMPro/Pro mice with solulin both delayed the 
disease onset (day 17 vs. day 10) and lessened the disease severity in comparison to PBS-
treated EAE TMPro/Pro mice (Fig. 3.10.1 A). The markedly improved outcome was associated 
with preserved myelination (LFB staining, Fig. 3.10.1 B) and reduced ROS-markers (ONOO-, 
8-oxo-dG) mice in both, 1 week after disease onset and 4 weeks after EAE induction (Fig. 
3.10.2 A-B).  
63 
 
 
  
Fig. 3.10.1: Interventions with aPC, p66Shc and soluble TM ameliorate EAE in TMPro/Pro mice 
A: EAE was induced in C57Bl/6 wt, TMPro/Pro, double mutant TMPro/Pro mice with restored levels of hPC 
(TMPro/Pro x hPChigh mice) or abolished p66Shc expression (TMPro/Pro x p66Shc-/-), and TMPro/Pro treated with 
soluble thrombomodulin (solulin). Clinical disease scores were significantly ameliorated in TMPro/Pro mice 
treated with solulin compared to TMPro/Pro mice. Scores are plotted as mean (N = 8) *P < 0.05; Student´s t-
test. B: left: Myelin staining of mouse spinal cord by using Luxol-Fast-Blue (LFB). Demyelination became 
apparent 1 week after EAE onset and was even more severe after 4 weeks of induction in EAE mice. In 
TMPro/Pro solulin treated and TMPro/Pro double mutant mice demyelination was reduced compared to TMPro/Pro 
mice. Scale bars: 200 µm. right: Bar graphs summarising demyelination of counted axons from Luxol-Fast-
Blue stainings (10 countings, N = 6). 
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Fig. 3.10.2: Interventions with aPC, p66Shc and soluble TM reduce oxidative stress in TMPro/Pro mice 
A: Representative images (left) and bar graphs (right) showing immunohistochemical staining of mouse 
spinal cord for nitrotyrosine (A) and 8-hydroxy-2’-deoxyguanosine (B). Nitrotyrosine and 8-hydroxy-2’-
deoxyguanosine are readily detectable after 1 week of EAE and are further increased after four weeks of 
EAE induction in TMPro/Pro mice. Nitrotyrosine and 8-hydroxy-2’-deoxyguanosine are ameliorated in TMPro/Pro 
double mutant mice and in TMPro/Pro mice treated with solulin. Brown, nitrotyrosine (A) or 8-hydroxy-2’-
deoxyguanosine (B) positive cells detected by horseradish peroxidase-3, 3´-diaminobenzidine reaction; blue, 
hematoxylin counterstain. Bar graphs summarise results obtained from eight different mice in each group. 
Scale bars: 20 µm. N = 8. **P < 0.01; Student´s t-test.  
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Thus, soluble thrombomodulin more efficiently than genetically restoring aPC levels or 
inhibiting mitochondrial ROS-generation ameliorates the disease course of EAE. The potent 
protective effect of solulin suggests that this may be a potential therapeutic approach.   
3.11 Soluble TM ameliorates EAE in wild type mice 
To ascertain whether solulin does not only compensate for the genetically superimposed 
impairment of TM function in TMPro/Pro mice, but may also be a potential therapeutic approach 
in mice expressing wild-type TM, we next evaluated the protective effect of solulin in EAE wt 
mice. Wt mice were treated with solulin following the induction of EAE, using the same 
protocol as above. In comparison to untreated or PBS-treated EAE wt mice solulin treatment 
delayed the disease manifestation and reduced the disease severity throughout the disease 
course (Fig. 3.11.1 A). In addition, solulin-treatment improved histological changes, reflecting 
myelin loss (Luxol-Fast-Blue), and normalised indices of ROS generation (ONOO-, 8-oxo-dG, 
Fig. 3.11.1 B-D).  
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Fig. 3.11.1: Soluble TM ameliorates EAE in wild type mice 
A: EAE was induced in C57/Bl6 wt mice and mice were left untreated or were treated with solulin or PBS for 
30 days and clinical disease scores were determined. Solulin treatment significantly ameliorated EAE 
disease score in wt mice treated with solulin. Scores are plotted as mean (N = 8) *P < 0.05, students t-test. 
B: Myelin staining of mouse spinal cord by using Luxol-Fast-Blue (LFB). Demyelination was severe after 4 
weeks in EAE mice. In solulin treated EAE wt mice demyelination was ameliorated compared to PBS-treated 
mice. Scale bars: 200 µm. right: Bar graphs summarising the demyelination of spinal cord sections (right, 10 
countings, N = 6). C: Representative images (left C, D) and bar graphs (right C, D) showing nitrotyrosine (C) 
and 8-hydroxy-2’-deoxyguanosine immunohistochemical stainings of mouse spinal cord. Nitrotyrosine (C) 
and 8-hydroxy-2’-deoxyguanosine (D) staining is reduced in EAE wt mice treated with solulin compared to 
PBS treated mice. Brown, nitrotyrosine/8-hydroxy-2’-deoxyguanosine positive cells detected by horseradish 
peroxidase-3, 3´-diaminobenzidine reaction; blue, hematoxylin counterstain. Bar graphs summarise results 
obtained from eight different mice in each group. Scale bars: 20 µm. *P < 0.05; **P<0.01; Student´s t-test.  
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3.12 Solulin reduces mitochondrial ROS in neuronal cells in vitro 
Considering the low level of endogenous aPC generation in TMPro/Pro mice and the 
established neuro-protective effects of solulin we next explored whether solulin cell-
autonomously reduces mitochondrial ROS generation in rat neuronal PC12 cells. PC12 were 
left untreated (PBS control) or treated with solulin (3 µg/ml; 1 h pre-incubation), stimulated 
with H2O2, and analysed after 15 and 60 min. Pre-treatment with solulin reduced 
mitochondrial ROS generation in neuronal PC12 cells at both time-points (Fig. 3.12.1 A-B). 
These findings demonstrate that solulin cell-autonomously restricts mitochondrial ROS 
production in neuronal cells.  
 
Fig. 3.12.1: Solulin decreased mitochondrial ROS in vitro 
A: Rat neuronal PC12 cells were treated with H2O2 and stained for MitoSOX. In PC12 cells pre-treated with 
solulin mitochondrial ROS, as indicated by MitoSOX, was reduced. Red: MitoSOX, blue: DAPI. Scale bars: 
20 µm. B: Summarising bar graphs obtained from 3 independent experiments. *P < 0.05; **P < 0.01; 
Student´s t-test.  
3.13 Soluble TM ameliorates non-immunological induced neuronal 
demyelination  
EAE is a disease primarily driven by an immunological reaction, but other mechanisms, such 
as increased ROS-generation, independently contribute to demyelination [92, 93]. The above 
data suggest that soluble TM conveys neuronal protection by reducing ROS-generation 
within the CNS and in neurons. To evaluate whether soluble TM convey a protective effect in 
a non-immunological demyelination model we analysed mice fed a cuprizone diet (0.2%) for 
5 weeks. Cuprizone induced marked demyelination in wt and to a larger degree in TMPro/Pro 
68 
 
mice after 5 weeks (Fig. 3.13.1), establishing that TM protects neuronal myelin in a non-
immunological demyelination model. Solulin treatment protected wt and – to a larger extend 
– TMPro/Pro mice from demyelination (Fig. 3.13.1). Hence, the protective effect of solulin 
against EAE is at least partially independent of an immune-modulatory function. 
  
Fig. 3.13.1 Soluble TM ameliorates non-immunological induced neuronal demyelination 
A: TEM images of mouse corpus callosum regions in the brain after feeding cuprizone diet for 5 weeks. 
Demyelination was aggravated in TMPro/Pro mice. Solulin treatment impaired demyelination in both, wt and 
TMPro/Pro mice. B: Bar graphs (down) summarising amount of ruptured nerve fibers. Scale bar: 1000 nm, N = 
5.* P < 0.05; ** P < 0.01; Student´s t-test.  
Taken together, these data demonstrate that basal endogenously impaired PC activation 
aggravates EAE, which is associated with increased ROS generation, impaired mitochondrial 
biogenesis, and impaired myelination in the CNS. These disease effects were partially 
reversible by restoring aPC or genetically restraining mitochondrial ROS generation, while 
treatment with solulin was more effective. The effects of TM on myelin are also apparent in a 
non-immunological model, revealing a function of TM in maintaining neuronal myelination 
independent of its immune-modulatory function.  
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4 Discussion 
4.1 Thrombomodulin-mediated protein C activation maintains neuronal 
function and nociception 
In the present study we demonstrate that TM-dependent PC activation constitutes a new 
endogenous pathway regulating nociception and neuron function within the CNS. The 
reduced nociceptive sensitivity in healthy mice with impaired PC-activation due to a point 
mutation in TM (TMPro) [71, 81] is related to a myelination defect in the CNS, while the 
function of peripheral nerves is unaffected. Disturbed myelination in the CNS of TMPro/Pro mice 
is associated with increased mitochondrial ROS generation and mitochondrial dysfunction 
characterised by impaired activity of the electron transport chain, an altered CL-composition, 
increased oxidised CL, and an increased frequency of mitochondrial DNA mutations. 
Importantly, pharmacological or genetical approaches to compensate for defective PC 
activation in TMPro/Pro mice correct these alterations and normalise the nociceptive sensitivity 
in TMPro/Pro mice. These studies uncover a basal neurological defect in mice with disruption of 
the – primarily – endothelial derived cytoprotective TM-PC system.  
Previously studies established a crucial neuroprotective function of PC in various disease 
models. Thus, aPC conveys protective effects in murine models of stroke, multiple sclerosis, 
amyotrophic lateral sclerosis (ALS) and neuronal apoptosis [11, 13, 45, 83, 94, 95]. In vitro 
aPC protects neurons from N-methyl-D-aspartate (NMDA) and staurosporine induced cell 
death [13]. Unlike in previous studies, in which the neuroprotective effect of aPC was only 
evaluated in the context in disease models, the current study establishes that TM-dependent 
PC activation is physiologically required for neuronal function. This suggests that impaired 
TM-function, as observed in various disease conditions such as atherosclerosis, diabetes, or 
sepsis [96-99], is sufficient to impair neuronal function, independently of additional disease 
related factors such as hyperglycemia or inflammation. Hence, we propose that impaired 
aPC generation is an independent and sufficient cause of impaired neurological function. 
Functional TM-deficiency, either due to targeted endothelial deletion (TMLoxP/LoxP x Tie2Cre) or 
the TMPro mutation, promotes fibrin deposition in various organs, but not in the brain [81, 
100]. These observations suggested already that TM-dependent PC-activation might 
modulate CNS function at least partially independent of fibrin-formation. Congruently, a 
cytoprotective PC mutant with markedly reduced anticoagulant function (3K3A-APC) 
provides potent neuroprotection [101, 102]. The observation that TM-dependent PC 
activation maintains myelin integrity, stabilises mitochondrial function, and restricts 
mitochondrial ROS generation in the CNS provides new insights into the mechanisms 
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through which aPC conveys neuroprotection. Intriguingly, disease models previously used to 
evaluate the neuro-protective effect of aPC are all linked with increased ROS generation [37, 
101, 103, 104]. The protective effects of aPC in neuronal disease models linked with 
increased ROS generation [37, 101, 103, 104] and the increased cerebral ROS generation in 
mice with impaired aPC generation (this study) are entirely congruent with aPC’s antioxidant 
effects in other in vitro and in vivo models [19, 44, 69, 105]. Impaired mitochondrial function 
is apparent in numerous diseases, including severe inflammation and sepsis [106-110], and 
hence stabilising of mitochondrial function may be a general phenomenon contributing to 
aPC’s cytoprotective effects. In the context of diabetic nephropathy loss of aPC generation 
can be compensated for by a concomitant loss of p66Shc expression, a mitochondrial targeted 
pro-oxidant redox-protein [19]. Both p66Shc deficiency and aPC convey neuro-protective 
effects in neuronal disease models such as EAE or stroke and neuronal apoptosis [13, 14, 
111-113], suggesting an interaction of p66Shc and aPC also in the context of neuronal 
disease. Alternatively, aPC’s antioxidant effect may be related to its ability to suppress 
superoxide dismutase-1 expression in the CNS [83]. Whether the neuro-protective effects of 
aPC are related to reduced expression of p66Shc, SOD1, or both remains to be evaluated.  
Neurons do not express TM [100] and hence TM expressed by other cells, most likely 
endothelial cells, must activate aPC, which is then transported across the BBB by endothelial 
EPCR [12, 36]. The EPCR facilitated transport of aPC across the BBB under physiological 
conditions is entirely congruent with aPC’s requirement for normal neuronal function, but at 
the same time implies that impaired EPCR mediated aPC transport across the BBB will 
induce neuronal defects similar to that observed in TMPro/Pro mice. Accordingly, aPC’s ability 
to reduce SOD1 expression in neuronal tissues is lost in mice with markedly reduced EPCR 
expression [83]. Endothelial dysfunction with reduced TM and EPCR function might hence 
endanger neuronal function through two independent and potentially additive effects: 
impaired PC-activation and impaired transport of aPC across the BBB. This may render the 
CNS particular vulnerable to diseases associated with reduced TM and EPCR function, such 
as vascular or inflammatory diseases.  
The myelination defect associated with aPC deficiency (this study) implies that aPC’s effects 
within the CNS depend at least partially on oligodendrocytes. Furthermore, the altered 
cerebral CL-profiled and (non-significant) alterations in the peripheral lipid profile in TMPro/Pro 
mice [114] suggest that aPC may modulate cellular function by altering the lipid profile. This 
may affect prostaglandin metabolism and thus indirectly interfere with nociception, as 
previously demonstrated for PAR agonists [34, 115]. Further studies are needed to define the 
different cell population within the CNS that are regulated by aPC and the mechanisms and 
receptors involved.  
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All four PARs are expressed in the nervous system [9]. As in other tissues, the role of PARs 
in the nervous system is context dependent [116]. The baseline conduction velocity of 
peripheral nerves obtained from TMPro/Pro mice was not different from that in wt mice. This 
does not exclude a role of PARs in regulating the function and nociception of peripheral 
nerves under disease conditions, as previously shown [117, 118], but establishes that under 
normal, non-diseased conditions loss of TM-dependent PC-activation primarily affects the 
function and ultrastructure of neurons within the CNS. The neuroprotective effect of aPC 
depends on PAR-3 both in vivo and in vitro [13, 83]. Of note, PAR-3 likewise conveys 
cytoprotective and antioxidant effects in renal cells [19, 22], suggesting that PAR-3 may 
regulate mitochondrial function in both brain and kidney. In regard to nociception studies 
hitherto focused on the role of PARs in afferent sensory neurons, linking the role of PARs to 
both pain-perception and inflammation [116, 119]. Importantly, loss of TM-dependent PC-
activation is sufficient to impair nociception and cause neuronal dysfunction within the CNS 
even in the absence of additional disease promoting stimuli. Congruently PAR1 or PAR4 
stimulation at sub-inflammatory doses increases the nociceptive threshold [35, 120]. The 
receptors conveying impaired nociception in TMPro/Pro mice remain to be established. 
Principally, increased PAR1 and / or PAR4 by thrombin or impaired PAR3 activation due to 
low aPC levels may contribute to the observed phenotype. In vivo studies with cell-specific 
deletion of receptors will be required to define the receptor mechanisms involved.  
Based on the current and previous results modulation of PAR signalling may provide a new 
therapeutic approach for peripheral neuropathies without provoking inflammation [121]. Such 
therapies will, however, not only affect nociception by modulating dorsal root ganglia [35, 
120], but may have additional effects on secondary neurons relaying signals to the brain. The 
preclinical evaluation of therapeutic approaches directly targeting PAR-signalling hence has 
to carefully address potential effects on the ultrastructure of central neurons.  
Importantly, restoring aPC in mice with defective aPC-generation reverses the neuronal 
dysfunction and normalises morphological alterations. Hence, pharmacological targeting the 
neuro-protective effect of aPC may constitute a save therapeutic approach to neuropathy 
and without causing structural and potentially harmful side-effects. Clinical studies evaluating 
the neuro-protective effect of the 3K3A-aPC mutant demonstrated a good safety profile in 
patients with acute stroke. Treatment of peripheral neuropathy would, however, require long-
term treatment, potentially for months or years. Potential side-effect during long-term 
treatment can not be excluded and need to be evaluated. Importantly, mice with constitute 
high aPC levels due to a transgene expressing a human hyper-activatable PC-mutant 
(aPChigh mice) [21] have normal behaviour and lack symptoms indicative of neuronal 
impairment even at high age, suggesting that pharmacological targeting of aPC-mediated 
neuro-protection may be feasible and safe.  
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4.2 The thrombomodulin protein C system protects from myelin loss in EAE 
After establishing a physiological role of TM-dependent PC activation for myelination we next 
evaluated whether TM-dependent PC activation aggravates the disease progression of 
demyelination models. Using mice with genetically enforced impaired TM-dependent PC 
activation we demonstrate a pathomechanistic relevance of reduced endogenous PC-
activation in EAE. Compensating for impaired PC activation reduces ROS generation within 
the CNS, maintains myelination, and improves the disease outcome. Of note, soluble TM has 
superior efficacy, delaying the disease onset and reducing the disease severity. The myelin-
protective effect is at least partially independent of the immune response, demonstrating that 
the TM-PC system conveys neuroprotective effects in EAE independent of its known 
immune-modulatory function. 
Considering the above data demonstrating that endogenous TM stabilises mitochondrial 
function and the myelin-sheet in the absence of an inflammatory disease process and the 
established functional interaction of mitochondrial dysfunction and myelination these 
observations suggest that loss of TM function alters myelin-axon interaction and promotes a 
primary cyto-degenerative process in resident CNS cells, which predisposes to 
demyelinating diseases. A pathogenetic relevance of coagulation regulators, including TM, is 
supported by a recent transcriptomic meta-analysis of MS and its experimental models 
suggested [122]. Based on these data we propose that alterations within the TM-PC system 
cause primary alterations of mitochondrial function in the CNS predisposing to demyelination 
diseases. This hypothesis, which is congruent with the “inside-out” theory in the 
pathogenesis of MS [123], awaits further experimental evaluation.  
Like aPC and solulin the thrombin-mutant W215A/E217A reduces demyelination in EAE-
mice, which, however, was attributed to an anti-inflammatory effect [40]. The ability of solulin 
and aPC to directly protect primary CNS cells such as neurons and astrocytes [37, 124], the 
impaired myelination in TM-deficient mice (section 3.1, 3.7), and the myelin protective effect 
of solulin in a non-immune demyelination model (section 3.13) suggest that TM-PC based 
therapeutic strategies may independently target two important pathomechanisms in MS: 
inflammation and demyelination. This dual therapeutic tactic may provide a rationale for the 
astonishing efficacy of TM-PC based therapeutic strategies in neuronal disease models [125-
127].  
In particular in regard to demyelinating diseases such as MS the myelin-protective effect of 
soluble thrombomodulin – and potentially of aPC and W215A/E217A thrombin – may provide 
superior efficacy when compare to current anti-inflammatory strategies. Soluble TM and aPC 
mutants lacking anticoagulant function (3K3A-APC) are being evaluated in clinical studies 
[49, 128, 129] and given the current results and the urgent need of new therapeutic 
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approaches for patients with multiple sclerosis we propose that these substances should be 
considered for clinical studies. Importantly, 3K3A-APC is largely devoid of an endogenous 
anticoagulant function and solulin mimics the “on-demand” anticoagulant properties of 
endogenous thrombomodulin, reducing the risk of haemorrhage and hence increasing the 
safety of these newly developed therapeutics [49]. 
The myelin-protective effect observed here is associated with reduce mitochondrial ROS 
generation within the CNS. Enhanced ROS generation is a well-established factor 
aggravating EAE and is thought to promote multiple sclerosis in humans. An anti-oxidant 
effect of aPC and solulin has been previously established in other disease models [130] [19, 
50, 95, 131] [82]. Furthermore, aPC protects from ROS-induced experimental ALS and 
reduces neuronal-cell death in stroke models by suppressing mitochondrial dysfunction [11, 
19]. Indeed, aPC inhibits p66Shc-mediated mitochondrial ROS-generation and cell death in 
the context of diabetic nephropathy [19, 21] and EAE (as demonstrated). Furthermore, we 
uncovered a mitochondria-stabilizing effect of aPC. Similar to aPC p66Shc modulates the 
outcome of neurological diseases such as stroke, dementia, and EAE [59, 112, 132] and 
neuronal cell death [113, 133, 134]. These similarities imply that TM-dependent PC activation 
suppresses p66Shc-dependent ROS-generation and neuronal damage not only in EAE, but 
also in other neurological diseases.   
Soluble thrombomodulin did not only improve the disease course in TMPro/Pro mice, but also in 
wild-type mice. The efficacy of soluble TM in mice primarily expressing functional TM is most 
likely explained by an inflammation induced loss of TM-function in EAE-wt mice, a typical 
finding in humans with and animal models of inflammatory diseases [17, 95, 135, 136]. We 
failed to detect increased aPC generation using an established protocol in mice following 
soluble TM injection [21, 81, 100]. This observation supports direct neuro-protective effects 
of soluble TM independently of PC-activation [137]. Yet it needs to be pointed out that we 
determined in vivo PC-generation 24 h after the last injection of soluble TM and hence an 
intermittent increase of TM-mediated aPC generation, which is sufficient for cytoprotective 
effects [19, 83], cannot be excluded.  
Inhibition of endogenous aPC using antibodies surprisingly resulted in protection from EAE 
[45], a finding ad odds with the current observation and those made by Han et al. [44] and 
Verbout et al. [40]. While Han and Verbout initiated treatment with aPC or W215A/E217A, 
respectively, at the time of maximal disease onset, Alabanza injected the inhibitory 
antibodies directly after induction of EAE, suggesting that the different timing may account for 
the observed disparities. However, in the current study genetic approaches were used, which 
mimic loss of aPC-generation or rescue of impaired TM-dependent PC-activation before 
disease onset, and solulin was injected starting on the 1st day of the disease induction. The 
current observations do not support the view that the disparities observed by Han, Verbout, 
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and Alabanza reflect the different timing of drug administration. Hence, other mechanisms 
must account for the observed disparities, such as hitherto unspecified effects of the PC-Ab 
complexes on the EAE-associated immune-response.  
Previously several neuro-protective mechanisms of the TM-PC system have been proposed, 
including reduced leukocyte infiltration into or diminished cell death within the CNS and 
stabilization of the blood-brain barrier [83, 138]. We identify a hitherto unknown mitochondria- 
and myelin-stabilizing effect of the TM-PC system, which may provide TM-PC based 
therapeutics with superior properties compared to current anti-inflammatory therapies. In 
addition, we demonstrate that solulin, a soluble TM variant, conveys superior protection from 
EAE. These results encourage the analyses of solulin or other therapeutic strategies 
employing mechanisms targeted by the TM-PC system in future translational studies.  
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5 Conclusion 
 
In this study we demonstrate that impairment of TM-dependent PC activation is sufficient to 
cause neuronal dysfunction in the absence of disease related processes, uncovering a 
hitherto unknown physiological function of TM-dependent PC activation for neuronal integrity. 
This newly discovered basal phenotype is associated with enhanced ROS production and 
mitochondrial dysfunction in the CNS. Importantly, these neuronal defects are reversible 
upon genetic or pharmacological substitution of aPC, establishing that this pathomechanisms 
is therapeutically amendable. These neuro-protective effects may provide TM-PC based 
therapeutics with superior properties compared to current anti-inflammatory therapies in 
demyelinating diseases as well as – potentially – in other neurodegenerative diseases. 
Loss of the physiological CNS-stabilising function of the TM-PC system aggravates the 
disease course of EAE. Importantly, the neuronal consequences of impaired TM-dependent 
PC activation accelerate demyelinating diseases independent of the immunological reaction, 
supporting the “inside-out” model of MS. Restoring aPC levels or genetically restraining 
mitochondrial ROS production partially reversed the clinical disease onset and disease 
symptoms. Soluble thrombomodulin has pronounced protective properties, which are 
superior to therapeutic application of aPC itself, and was able to markedly improve the 
clinical EAE symptoms. These results provide new impetus for future studies exploring the 
involved mechanisms in greater detail and for translational studies evaluating TM-PC-based 
therapeutic strategies in patients with demyelinating diseases.   
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